Viral infections evidence library

Hepatitis B

A living PubMed evidence library for acute and chronic hepatitis B, antiviral therapy, monitoring, complications, prevention, and emerging cure research.

PubMed only Research ranked Conflicts shown Data downloadable

Living evidence synopsis

What the current PubMed collection shows.

Alexandria currently organizes 1,233 non-retracted PubMed-indexed records for Hepatitis B. The structured collection includes 22 guideline or consensus records, 126 evidence syntheses/systematic reviews/meta-analyses, and 114 randomized or phase III studies. 360 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 981 of 1,233 included records.

Engine 0.3.2 Snapshot v8 Updated 2026-08-14 Download source data · CSV

PubMed records1,233Non-retracted records included

Last 24 months360Records found by the recent-research search

High-priority evidence240Syntheses, reviews, randomized and phase III studies

Effect estimates411Machine-readable values extracted from abstracts

COI statements79.6%Coverage within PubMed records

Funding records326PMIDs with grant/funding metadata

Evidence data

Research landscape

Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.

Publication activity

Records by publication year

Latest 12 represented years

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

160

2025

916

2026

Evidence composition

Study designs

Other or unclassified653

Preclinical/laboratory128

Randomized trials105

Meta-analyses77

Case reports70

Cohort studies59

Systematic reviews49

Prospective cohorts27

Clinical guidelines22

Observational studies17

Transparency

Conflict-of-interest reporting

Reported no conflicts482

COI statement present407

Not reported in PubMed record252

Declared financial/industry relationship92

Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.

Abstract result signals

Extracted result direction

Not extractable from abstract1116

Neutral/null signal43

Harm signal34

Supportive signal34

Mixed signal6

Reported outcomes

Numerical results extracted from PubMed abstracts

Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.

Non-pooled ratio measures

Hazard, risk, and odds ratios reported in abstracts

Reference = 1.0

0.250.51.02.04.0

cirrhosis Odds Ratio · PMID 41556856 · 2026

4.00

overall survival Hazard Ratio · PMID 41208807 · 2026

0.58

overall survival Odds Ratio · PMID 41208807 · 2026

3.17

survival Hazard Ratio · PMID 41208807 · 2026

0.48

not_reported Odds Ratio · PMID 42140217 · 2026

7.00

not_reported Odds Ratio · PMID 41206665 · 2026

0.79 95% CI 0.59–1.04

not_reported Odds Ratio · PMID 41554267 · 2026

300.00

not_reported Odds Ratio · PMID 41554267 · 2026

300.00

survival Hazard Ratio · PMID 41764966 · 2026

0.67

survival Hazard Ratio · PMID 41764966 · 2026

0.58

survival Hazard Ratio · PMID 41764966 · 2026

0.84

survival Hazard Ratio · PMID 41764966 · 2026

0.75

survival Hazard Ratio · PMID 41764966 · 2026

0.88

survival Hazard Ratio · PMID 41764966 · 2026

0.71

View extracted numerical results 60

Publication	Outcome	Measure	Reported value	Source
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.Gastroenterology · 2026	cirrhosis	Odds Ratio	4.0	PMID 41556856
Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses.International journal of surgery (London, England) · 2026	overall survival	Hazard Ratio	0.58	PMID 41208807
Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses.International journal of surgery (London, England) · 2026	overall survival	Odds Ratio	3.17	PMID 41208807
Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses.International journal of surgery (London, England) · 2026	survival	Hazard Ratio	0.48	PMID 41208807
Evaluating liver fibrosis in chronic hepatitis B patients using multi-compartment restriction spectrum imaging.The British journal of radiology · 2026	not_reported	Percentage Comparison	75.0percent vs 44.6percent P = .033	PMID 41915030
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial.The lancet. HIV · 2026	not_reported	Odds Ratio	7.0	PMID 42140217
Human papillomavirus vaccinations' impact on preterm birth rates.European journal of public health · 2026	not_reported	Odds Ratio	0.79 95% CI 0.59–1.04	PMID 41206665
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial.The lancet. Gastroenterology & hepatology · 2026	not_reported	Odds Ratio	300.0	PMID 41554267
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial.The lancet. Gastroenterology & hepatology · 2026	not_reported	Odds Ratio	300.0	PMID 41554267
Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	survival	Hazard Ratio	0.67	PMID 41764966
Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	survival	Hazard Ratio	0.58	PMID 41764966
Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	survival	Hazard Ratio	0.84	PMID 41764966
Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	survival	Hazard Ratio	0.75	PMID 41764966
Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	survival	Hazard Ratio	0.88	PMID 41764966
Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	survival	Hazard Ratio	0.71	PMID 41764966
Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	not_reported	Hazard Ratio	0.84	PMID 41764966
Differential Efficacy of Immunotherapy for Hepatocellular Carcinoma by Aetiology: A Systematic Review and Meta-Analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026	not_reported	Hazard Ratio	0.91	PMID 41764966
Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B.Hepatology (Baltimore, Md.) · 2026	HBsAg loss	Odds Ratio	12.65 95% CI 1.58–101.51	PMID 41186417
Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B.Hepatology (Baltimore, Md.) · 2026	HBsAg loss	Odds Ratio	47.17 95% CI 2.79–797.35	PMID 41186417
Improved appropriateness of electronic consultations in primary care with ongoing liver disease education.Journal of telemedicine and telecare · 2026	not_reported	Odds Ratio	2.001 95% CI 1.36–2.946 p < 0.001	PMID 41359013
Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis B.Liver international : official journal of the International Association for the Study of the Liver · 2026	not_reported	Odds Ratio	700.0	PMID 42163628
Early antibiotic exposure reduces progression-free survival in unresectable hepatocellular carcinoma patients treated with TACE plus TKI and ICI therapy: a propensity score-matched analysis.BMC gastroenterology · 2026	not_reported	Odds Ratio	30.0	PMID 42458307
Awareness of Cancer Among Japanese Junior and Senior High School Students and Relevant Factors.Asian Pacific journal of cancer prevention : APJCP · 2026	not_reported	Odds Ratio	2.28 p < 0.001	PMID 42517691
Awareness of Cancer Among Japanese Junior and Senior High School Students and Relevant Factors.Asian Pacific journal of cancer prevention : APJCP · 2026	not_reported	Odds Ratio	1.04 p < 0.001	PMID 42517691
Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis.The lancet. Gastroenterology & hepatology · 2026	HBV DNA suppression	Risk Ratio	31.0	PMID 41839198
Development and Validation of a Prediction Model for Overt Hepatic Encephalopathy (OHE) After Transjugular Intrahepatic Portosystemic Shunt: A Multicenter Retrospective Study.Journal of clinical and experimental hepatology · 2026	not_reported	Odds Ratio	1.35 95% CI 1.15–1.59 P < 0.001	PMID 41815830
Development and Validation of a Prediction Model for Overt Hepatic Encephalopathy (OHE) After Transjugular Intrahepatic Portosystemic Shunt: A Multicenter Retrospective Study.Journal of clinical and experimental hepatology · 2026	not_reported	Odds Ratio	1.08 95% CI 1.05–1.12 P < 0.001	PMID 41815830
Development and Validation of a Prediction Model for Overt Hepatic Encephalopathy (OHE) After Transjugular Intrahepatic Portosystemic Shunt: A Multicenter Retrospective Study.Journal of clinical and experimental hepatology · 2026	not_reported	Odds Ratio	7.64 95% CI 3.5–17.55 P < 0.001	PMID 41815830
Development and Validation of a Prediction Model for Overt Hepatic Encephalopathy (OHE) After Transjugular Intrahepatic Portosystemic Shunt: A Multicenter Retrospective Study.Journal of clinical and experimental hepatology · 2026	not_reported	Odds Ratio	2.35 95% CI 1.19–4.77 P < 0.001	PMID 41815830
Development and Validation of a Prediction Model for Overt Hepatic Encephalopathy (OHE) After Transjugular Intrahepatic Portosystemic Shunt: A Multicenter Retrospective Study.Journal of clinical and experimental hepatology · 2026	not_reported	Odds Ratio	3.76 95% CI 1.15–12.64 P < 0.001	PMID 41815830
Development and Validation of a Prediction Model for Overt Hepatic Encephalopathy (OHE) After Transjugular Intrahepatic Portosystemic Shunt: A Multicenter Retrospective Study.Journal of clinical and experimental hepatology · 2026	not_reported	Odds Ratio	0.12 95% CI 0.05–0.26 P < 0.001	PMID 41815830
Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study.Lung cancer (Amsterdam, Netherlands) · 2026	not_reported	Percentage Comparison	30.2percent vs 35.8percent P = 0.428	PMID 42531850
Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study.Lung cancer (Amsterdam, Netherlands) · 2026	not_reported	Percentage Comparison	54.7percent vs 54.5percent P = 0.428	PMID 42531850
Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.Alimentary pharmacology & therapeutics · 2026	HBsAg loss	Hazard Ratio	0.28 p < 0.001	PMID 40842267
Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.Alimentary pharmacology & therapeutics · 2026	HBsAg loss	Hazard Ratio	1.14 p < 0.001	PMID 40842267
Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.Alimentary pharmacology & therapeutics · 2026	HBsAg loss	Odds Ratio	0.5 p < 0.001	PMID 40842267
Clinical Trials for Curing Chronic Hepatitis B: A Comprehensive Analysis of Trial Design Considerations and Their Association With Trial Performance.Journal of gastroenterology and hepatology · 2026	not_reported	Hazard Ratio	0.819 95% CI 0.71–0.945	PMID 41830065
Clinical Trials for Curing Chronic Hepatitis B: A Comprehensive Analysis of Trial Design Considerations and Their Association With Trial Performance.Journal of gastroenterology and hepatology · 2026	not_reported	Hazard Ratio	0.897 95% CI 0.816–0.987	PMID 41830065
Clinical Trials for Curing Chronic Hepatitis B: A Comprehensive Analysis of Trial Design Considerations and Their Association With Trial Performance.Journal of gastroenterology and hepatology · 2026	not_reported	Hazard Ratio	0.936 95% CI 0.879–0.997	PMID 41830065
Clinical Trials for Curing Chronic Hepatitis B: A Comprehensive Analysis of Trial Design Considerations and Their Association With Trial Performance.Journal of gastroenterology and hepatology · 2026	not_reported	Odds Ratio	2.82 95% CI 1.16–7.08	PMID 41830065

Research transparency

Funding and conflicts of interest

Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.

COI statement coverage79.6%252 records have no COI statement exposed in PubMed.

Funding metadata coverage26.4%Coverage indicates whether grant/funding metadata was present, not independence or study quality.

Most frequently reported funding agencies

National Natural Science Foundation of China73

NIAID NIH HHS38

NIDDK NIH HHS23

National Key Research and Development Program of China19

NCI NIH HHS19

National Science and Technology Council11

NIH HHS11

NIDA NIH HHS10

View records with declared financial or industry relationships 12

Assessing the impact of buprenorphine for opioid use disorder on infectious disease management.

Declaration of competing interest Jamie Lo and Sabrina Gaiazov were employees of Indivior Inc. and William Pratt was an employee of Veradigm Inc. at the time the study was conducted. Anusorn Thanataveerat, Jennifer Falk, Ni Zeng, Stephanie Wall, and Taylor Ryan, are full-time employees of Veradigm Inc., which was contracted by Indivior Inc. to conduct this research.

PMID 42081946 · 2026

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.

Declaration of interests M-FY serves as an adviser or a consultant for AbbVie, AlloVir International, Arbutus Biopharma, Bristol Myers Squibb, ClearB Therapeutics, Dicerna Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Roche, and Spring Bank Pharmaceuticals; and receives grant or research support from Assembly Biosciences, Arrowhead Pharmaceuticals, Bristol Myers Squibb, Fujirebio Diagnostics, Gilead Sciences, Merck Sharp & Dohme, Roche, Spring Bank Pharmaceuticals, and Sysmex Corp. TA serves as an adviser or a consultant for AbbVie, Antios Therapeutics, Enyo Pharma, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, and Vir Biotechnology. IMJ serves as a consultant for Aligos, Arbutus, Janssen, and Gilead; has received research funds from Janssen and Assembly Biosciences; and serves on a data monitoring committee for GlaxoSmithKline. MRB serves as a consultant and speaker for AbbVie, Gilead Sciences, Janssen, Eisai, MSD, and Roche. HLAJ received grants from AbbVie, Arbutus, Gilead Sciences, Janssen, and Roche, and is a consultant for Arbutus, Arena, Enyo, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Roche, Vir Biotechnology, and Viroclinics. TT has received lecturer fees Bristol Myers Squibb, Gilead Sciences, and GlaxoSmithKline; research funding from Janssen and Gilead Sciences; and consulting fees from Janssen. JLH serves as an adviser or a consultant for Aligos, Assembly, Gilead Sciences, Johnson & Johnson, and Roche, and receives grant or research support from Bristol Myers Squibb. TNK, TL, MBe, RK, CG-A, CM, JJ, TV, OL, US, and MBi are Janssen employees and are Johnson & Johnson stockholders.

PMID 37442152 · 2023

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Amanda J. Nicoll advises and is on the speakers’ bureau for Ipsen, Eisai, Roche, and AstraZeneca. Simone I. Strasser advises and is on the speakers’ bureau for Gilead, Eisai, Norgine, Roche, Chiesi, and AstraZeneca. She advises Pfizer and MSD and is on the speakers’ bureau for Otsuka and AbbVie. Gail Matthews advises and received grants from Gilead and ViiV. She advises AstraZeneca and received grants from AbbVie. Kumar Visvanathan consults, advises, and is on the speakers’ bureau for Gilead. He advises ViiV. The remaining authors have no conflicts to report.

PMID 37459199 · 2023

Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study.

Su Jong Yu received compensation for lectures from Bayer HealthCare Pharmaceuticals. Jeong-Hoon Lee received compensation for lectures from GreenCross Cell, Daewoong Pharmaceuticals and Gilead Korea; Jung-Hwan Yoon received a research grant from Bayer HealthCare Pharmaceuticals, Bukwang Pharmaceuticals and Daewoong Pharmaceuticals; and Yoon Jun Kim received research grants from BTG, AstraZeneca, Gilead Sciences, Daewoong, Bayer, Samjin, and Yuhan Pharmaceuticals.

PMID 37463687 · 2023

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

Jordan J. Feld has received research grants from Altimmune, AbbVie, Gilead Sciences, Janssen, GlaxoSmithKline, Roche, and Vir Biotechnology Inc., and is a consultant for AbbVie, Bluejay Therapeutics, Gilead Sciences, Janssen, GlaxoSmithKline, Roche, and Vir Biotechnology Inc. Bettina E. Hansen has received grants from Mirum, Gilead Sciences, and Ipsen, and is a consultant for Intercept, Mirum, Ipsen, Gilead Sciences, Falk, Advanz, and ChemomAb. Harry L.A. Janssen has received grants from Gilead Sciences, GlaxoSmithKline, Janssen, Roche, and Vir Biotechnology Inc., and is a consultant for Aligos, Gilead Sciences, GlaxoSmithKline, Grifols, Roche, Vir Biotechnology Inc., Precision Biosciences, Academic Medical Education, and H.C. Wainwright & Co. The remaining authors have no conflicts to report.

PMID 41335575 · 2025

The changing epidemiology of primary liver cancer in the 21st century.

Conflicts of interest TCFY served as an advisory committee member and a speaker for Gilead Sciences. He has received a research grant from Gilead Sciences. SAK has served as an advisory board member for Astra Zeneca, Clarivate, Taiho and a speaker for a Servier sponsored educational event. HES served as consultant for NovoNordisk and Madrigal, and received research grant funding from NovoNordisk. Please refer to the accompanying ICMJE disclosure forms for further details.

PMID 42542384 · 2026

Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B.

Conflicts of interest Roche MagNA and COBAS are registered trademarks of F. Hoffmann-La Roche Ltd. M Savarese and C Lau are employed by GSK. A Koenig, J Bouquet, SD Speer, CM Livingston, L Maynard, S You, M Paff, D Theodore, R Elston, J Walker, and J Cremer are employed by GSK and hold financial equities in GSK. J Cremer, M Paff, D Theodore, and R Elston are named inventors on pending bepirovirsen patent applications. E Angelini was an employee of GSK at the time of the study. N Galwey and P Yates were employees and held financial equities in GSK at the time of study. Please refer to the accompanying ICMJE disclosure forms for further details.

PMID 41544767 · 2026

Multidisciplinary management of thyroid eye disease (TED) in patients with latent tuberculosis or chronic hepatitis B.

Declarations. Ethics approval and consent to participate: This retrospective audit was registered and approved by Imperial College Healthcare National Health Service (NHS) Trust, London. Data were anonymised and confidentiality was maintained throughout. This audit adhered to the tenets of the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: Miss Vickie Lee is: Principal Investigator for the Horizon, Viridian, Argenx, LIDS and Lassen Trials. British Oculoplastic Surgery Society (BOPSS) National Lead for Thyroid Eye Disease. Advisory board and consulting for Amgen, Viridian, Argenx and Roche Pharmaceuticals. Honoraria from Amgen.

PMID 41612401 · 2026

A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.

Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The authors declared the following conflicts of interest with respect to the research, authorship, and/or publication of this article: • Min Wu, Kha Le, Tse-I Lin, Lawrence Blatt, Sushmita Chanda are the employees of Aligos and owned equity in the company. • John Fry was an employee of Aligos Therapeutics at the time of study conduct and owned equity in the company. • Ed Gane is a consultant for Aligos, Assembly, AusperBio, Gilead, GSK, Janssen, Roche, Surrozen, VIR, Virion, Precision Biosciences, Tune, and has given lectures sponsored AbbVie, Roche Diagnostics. In addition, grants are provided by AbbVie for community HepC Microelimination Programme.

PMID 41268712 · 2025

Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.

Declaration of competing interest Bertoletti A and Le Bert N are founders and hold stock of T Cell Diagnostics (TCD). Bertoletti A is also a consultant of Brii-Biosciences.

PMID 42214471 · 2026

Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signaling.

Conflicts of interest RNAscope is a registered trademark of Advanced Cell Diagnostics (ACD). FlowJo is a registered trademark of BD Life Sciences. Cyto-Fast is a registered trademark of BioLegend. SIMOA is a registered trademark of Quanterix Corporation. COBAS is a trademark of Roche Diagnostics Operations, Inc. DiscoveryMAP is a trademark of Myriad RBM. Usha Nivarthi, Anne DeHart, and Kristen Jones, are employed by GSK. Megan E. Ermler, William Jordan, Amitabh Das, Nicholas Galwey, Valeriia Sherina, Avijit Ray, Melanie Paff, Daren Austin, Jennifer M. Singh, Bao Hoang, Rebecca L. Terry, and Jimmy Tarrant are employed by GSK and hold financial equities in GSK. Jared L. Delahaye, Shihyun You, and Dickens Theodore are employed by GSK, have financial equities in GSK, and have patent applications with GSK. Please refer to the accompanying ICMJE disclosure forms for further details.

PMID 42264034 · 2026

Chinese medicinal herbs for chronic hepatitis B.

We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (e.g., employment, consultancy, stock ownership, honoraria, expert testimony).

PMID 11279742 · 2001

Gastroenterology · 2026

DESCRIPTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in patients with cirrhosis. Although advancements in surgical, locoregional, and systemic therapies have improved outcomes for patients with early-stage HCC, most cases are diagnosed at later stages due to both the limitations of currently recommended surveillance modalities and their underuse, with fewer than 1 in 4 patients with cirrhosis receiving surveillance for this tumor. Current guidelines recommend semiannual surveillance with ultrasound and α-fetoprotein, but this strategy has suboptimal sensitivity, and alternative imaging techniques (eg, computed tomography and magnetic resonance imaging) have …

PMID 42017860

Journal of clinical medicine · PMID 42590149

Treatment Options Studied in the PubMed Collection

These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.

preliminary evidence

Antiviral Agents

134 linked PMIDs49562 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, functional cure, hepatocellular carcinoma, HBsAg loss, adverse events, cirrhosis, mortality, relapse
Populations represented: general population; chronic hepatitis B; chronic hepatitis B; HBsAg; chronic hepatitis B; HBsAg; HBeAg; HBsAg; HBV DNA; chronic hepatitis B; HBeAg-negative chronic hepatitis B; HBsAg; HBeAg; HBV DNA
Mechanism: Despite its clinical relevance, very few studies have explored direct targeting of eIF4E's cap-binding function using small molecules as a therapeutic strategy Our findings not only reinforce the feasibility of targeting eIF4E in cancer but also demonstrate that repurposing FDA-approved drugs like Entecavir could offer a practical and efficient route to therapeutic intervention

PMID 40306834 PMID 42117446 PMID 35975904 PMID 39820185 PMID 42538702 PMID 42127258 PMID 41799526 PMID 42413584

moderate-confidence evidence

Hepatitis B Surface Antigens

99 linked PMIDs211770 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, functional cure, HBsAg loss, adverse events, cirrhosis, hepatocellular carcinoma, relapse, response rate
Populations represented: HBsAg; HBsAg; HBV DNA; chronic hepatitis B; HBsAg; general population; chronic hepatitis B; HBsAg; HBeAg; chronic hepatitis B; HBeAg-negative chronic hepatitis B; HBsAg; HBeAg; HBV DNA
Mechanism: The risk of HBVr is influenced by the mechanism of action and the duration of immunosuppressants and immunomodulators, the underlying disease for which these drugs are used, and the virological patient's profile Targeting SPECT-1 as an addition to the CSP in the same vaccine may enhance immune response and protection

PMID 41219059 PMID 42287020 PMID 41427832 PMID 41390946 PMID 41721875 PMID 42069606 PMID 41749120 PMID 41557957

moderate-confidence evidence

DNA, Viral

62 linked PMIDs31305 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, HBsAg loss, cirrhosis, hepatocellular carcinoma, relapse, adverse events, functional cure, serious adverse events
Populations represented: general population; HBsAg; HBV DNA; HBV DNA; chronic hepatitis B; HBeAg-negative chronic hepatitis B; HBsAg; HBeAg; HBV DNA; HBsAg; HBeAg; HBV DNA; chronic hepatitis B; HBsAg; HBeAg; HBV DNA
Mechanism: Lonafarnib (LNF) is an investigational drug targeting hepatitis delta virus (HDV) but not hepatitis B virus (HBV), providing a unique opportunity to model HDV kinetics and how changes in HDV affect HBV Conserved regions among Indian HBV and HCV genotypes are selected as targets of detection

PMID 35253969 PMID 36047593 PMID 42217280 PMID 41967140 PMID 41951368 PMID 39962085 PMID 41149352 PMID 40523423

higher-confidence evidence

Hepatitis B Vaccines

35 linked PMIDs999517 reported cumulative sample signal

Research status: conflicting evidence
Outcomes represented: reported clinical outcomes, adverse events, functional cure, cirrhosis, hepatocellular carcinoma, HBsAg loss, mortality
Populations represented: general population; chronic hepatitis B; HBsAg; HBsAg; HBV DNA; children
Mechanism: Substantial institutional variation in vaccination practices is associated with disparities beyond what would be expected from patient demographics alone, highlighting the need for system-level interventions targeting organizational factors to achieve equitable vaccination coverage

PMID 41935745 PMID 39820185 PMID 35049430 PMID 41555034 PMID 39420477 PMID 41622674 PMID 41936264 PMID 39819251

moderate-confidence evidence

tenofovir

30 linked PMIDs3950 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, adverse events, functional cure, ALT normalization, HBsAg loss, virologic suppression, mortality
Populations represented: general population; chronic hepatitis B; HBsAg; HBV DNA; HBsAg; chronic hepatitis B; HBsAg; HBeAg; HBV DNA; ALT; advanced; HBsAg
Mechanism: Regarding antenatal screening, adding tenofovir prophylaxis for HBsAg-positive pregnant women was more cost-effective than intervention solely targeting infants

PMID 39820185 PMID 42542601 PMID 41867101 PMID 42467629 PMID 42547309 PMID 41799526 PMID 40984668 PMID 42355610

moderate-confidence evidence

Hepatitis B Antibodies

16 linked PMIDs24126 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, adverse events, virologic suppression
Populations represented: general population; HBsAg; HBsAg; HBV DNA; HBV DNA
Mechanism: In this study, we established a sensitive and reliable immunospot assay for the visible quantitative detection of HBV infection based on an excellent detection antibody targeting the HBV core protein

PMID 41622674 PMID 39819251 PMID 42538702 PMID 41838860 PMID 35044877 PMID 41810956 PMID 42287020 PMID 41390946

preliminary evidence

Biomarkers

16 linked PMIDs3245 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: mortality, reported clinical outcomes, hepatocellular carcinoma, cirrhosis, HBsAg loss, functional cure, relapse
Populations represented: general population; chronic hepatitis B; HBsAg; HBeAg; chronic hepatitis B; chronic hepatitis B; HBsAg; HBeAg; ALT; chronic hepatitis B; advanced; ALT; chronic hepatitis B; HBsAg; HBV DNA
Mechanism: These findings provide new directions for the study of ACLF pathogenesis and identifying potential drug targets, which are conducive to early clinical decision-making Targeting MANF may represent a potential therapeutic strategy for preventing and treating digestive diseases

PMID 41776162 PMID 41255250 PMID 42577490 PMID 42538702 PMID 41838860 PMID 42065201 PMID 41758058 PMID 42438905

limited evidence

RNA, Viral

16 linked PMIDs— reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, recurrence, relapse
Populations represented: general population; chronic hepatitis B; HBV DNA; HBsAg; chronic hepatitis B; HBeAg; chronic hepatitis B; HBsAg; HBV DNA
Mechanism: The assay demonstrated 95% limit of detection (LoD) values ranging from 2.42 to 6.65 copies/reaction across targets with high specificity This innovative platform enabled simultaneous amplification of two pgRNA targets within a single-tube RT-MIRA reaction, allowing dual-target detection via one-step amplification

PMID 42200523 PMID 40626720 PMID 41967140 PMID 41367298 PMID 40750193 PMID 39044084 PMID 42330277 PMID 39044076

moderate-confidence evidence

Hepatitis B e Antigens

13 linked PMIDs909 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: adverse events, functional cure, HBsAg loss, serious adverse events, cirrhosis, reported clinical outcomes, HBeAg seroconversion, hepatocellular carcinoma
Populations represented: chronic hepatitis B; HBsAg; HBeAg; chronic hepatitis B; HBeAg-negative chronic hepatitis B; HBsAg; HBeAg; HBV DNA; chronic hepatitis B; HBsAg; HBeAg; ALT; chronic hepatitis B; HBsAg; HBeAg; HBV DNA; ALT; chronic hepatitis B; HBsAg; HBeAg; ALT; children; chronic hepatitis B; HBsAg; HBeAg; HBV DNA
Mechanism: INTERPRETATION: Single and multiple doses of imdusiran were safe and well tolerated in healthy individuals and in individuals with chronic hepatitis B, supporting drug development of imdusiran as a future treatment targeting functional cure for chronic hepatitis B BACKGROUND & AIMS: Selgantolimod (GS-9688) is a Toll-like receptor 8 (TLR8) agonist that suppresses HBV in vitro

PMID 42173110 PMID 38976867 PMID 38133554 PMID 35964909 PMID 41656920 PMID 42438905 PMID 39094743 PMID 37062574

preliminary evidence

Interferon-alpha

12 linked PMIDs221 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: HBsAg loss, reported clinical outcomes, functional cure, response rate, recurrence
Populations represented: chronic hepatitis B; HBeAg-negative chronic hepatitis B; HBsAg; HBeAg; HBV DNA; chronic hepatitis B; chronic hepatitis B; HBsAg; chronic hepatitis B; HBsAg; HBV DNA; ALT; chronic hepatitis B; HBsAg; ALT
Mechanism: Not explicitly reported in the retrieved PubMed metadata or abstracts.

PMID 39094743 PMID 42052091 PMID 42358965 PMID 40838600 PMID 42209159 PMID 41836379 PMID 42039194 PMID 40528594

preliminary evidence

Alanine Transaminase

11 linked PMIDs1270 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, hepatocellular carcinoma, virologic suppression, ALT normalization, HBsAg loss, functional cure, adverse events, serious adverse events
Populations represented: chronic hepatitis B; HBsAg; HBV DNA; ALT; chronic hepatitis B; chronic hepatitis B; ALT; chronic hepatitis B; HBsAg; HBeAg; ALT; chronic hepatitis B; HBsAg; HBV DNA; chronic hepatitis B; HBV DNA; ALT
Mechanism: BACKGROUND: Treatment with bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus (HBV) transcripts, has the potential to result in a functional cure, defined by at least 24 weeks of a sustained HBV DNA level below the lower limit of quantification (LLOQ) and hepatitis B surface antigen (HBsAg) loss after fixed-duration therapy

PMID 42104239 PMID 35359064 PMID 42299581 PMID 42366559 PMID 42015653 PMID 42067192 PMID 42206582 PMID 41846518

preliminary evidence

Polyethylene Glycols

11 linked PMIDs221 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, functional cure, HBsAg loss, response rate, recurrence
Populations represented: chronic hepatitis B; chronic hepatitis B; HBsAg; chronic hepatitis B; HBeAg-negative chronic hepatitis B; HBsAg; HBeAg; HBV DNA; chronic hepatitis B; HBsAg; HBV DNA; ALT; chronic hepatitis B; HBsAg; ALT
Mechanism: Not explicitly reported in the retrieved PubMed metadata or abstracts.

PMID 40838600 PMID 42209159 PMID 41836379 PMID 42039194 PMID 40528594 PMID 41807303 PMID 42216052 PMID 39094743

preliminary evidence

tenofovir disoproxil fumarate

9 linked PMIDs838 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes
Populations represented: chronic hepatitis B; HBsAg; HBV DNA; general population
Mechanism: Not explicitly reported in the retrieved PubMed metadata or abstracts.

PMID 40984668 PMID 42355610 PMID 42479363 PMID 42298392 PMID 42521358 PMID 42538704 PMID 42388965 PMID 42542601

limited evidence

COVID-19 Vaccines

9 linked PMIDs506 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, adverse events, mortality
Populations represented: general population
Mechanism: We evaluate vaccines targeting influenza, Streptococcus pneumoniae, SARS-CoV-2, and other relevant pathogens, and explore determinants influencing vaccine efficacy, including optimal timing, formulation, and patient-specific immune parameters

PMID 41686169 PMID 42536938 PMID 42090582 PMID 41349254 PMID 40884514 PMID 40233885 PMID 41780104 PMID 39622209

preliminary evidence

entecavir

8 linked PMIDs290 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, functional cure, virologic suppression, ALT normalization
Populations represented: chronic hepatitis B; general population; chronic hepatitis B; ALT
Mechanism: Mechanistically, KP strongly inhibited the transcriptional activity of the HBV core promoter (Cp), and enhanced the phosphorylation of both extracellular signal-regulated kinase (ERK) and its downstream target forkhead box protein O1 (FOXO1) Despite its clinical relevance, very few studies have explored direct targeting of eIF4E's cap-binding function using small molecules as a therapeutic strategy

PMID 42479363 PMID 42291993 PMID 41798742 PMID 42174232 PMID 42138483 PMID 41799526 PMID 41518564 PMID 42015653

preliminary evidence

tenofovir alafenamide

8 linked PMIDs290 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: functional cure, adverse events, reported clinical outcomes, virologic suppression, ALT normalization
Populations represented: general population; chronic hepatitis B; chronic hepatitis B; ALT; first-line
Mechanism: Not explicitly reported in the retrieved PubMed metadata or abstracts.

PMID 42174232 PMID 42138483 PMID 41763570 PMID 42503991 PMID 42479363 PMID 42298392 PMID 42015653 PMID 41144075

preliminary evidence

Immune Checkpoint Inhibitors

7 linked PMIDs7301 reported cumulative sample signal

Research status: mostly supportive
Outcomes represented: hepatocellular carcinoma, adverse events, functional cure, overall survival, progression-free survival, objective response rate, response rate, mortality
Populations represented: general population; chronic hepatitis B; HBsAg; advanced; first-line
Mechanism: Here, we conducted a mechanistic study parallel to our phase 2 trial of perioperative anti-PD-1 therapy in patients with resectable recurrent hepatocellular carcinoma (HCC) (NCT04615143) to study its mechanism of action Mechanistically, HBcAg is exported into the extracellular space, triggering local B cell and antibody responses and complement activation

PMID 42462708 PMID 42148120 PMID 42495600 PMID 42220514 PMID 41794163 PMID 41764966 PMID 41701457

limited evidence

Vaccines

7 linked PMIDs262 reported cumulative sample signal

Research status: insufficiently reported
Outcomes represented: reported clinical outcomes, mortality
Populations represented: general population; children
Mechanism: The model included nine Greek NIP routine vaccines for children aged 2 months to 11 years, targeting 14 vaccine-preventable diseases: diphtheria, hepatitis A, hepatitis B, Haemophilus influenzae type B, measles, meningococcal disease, mumps, pertussis, pneumococcal disease, poliomyelitis, rotavirus, rubella, tetanus, and varicella

PMID 41666790 PMID 41656735 PMID 42537288 PMID 35417187 PMID 40233885 PMID 41313491 PMID 40976961

Conflicting Research

higher-confidence evidence

Antiviral Agents · multiple reported outcomes

34 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 29benefit: 4harm: 1

PMID 38805690 PMID 26563120 PMID 39528324 PMID 41138575 PMID 41085094 PMID 41988576 PMID 40607962 PMID 11736720 PMID 41186228 PMID 37400385

higher-confidence evidence

Hepatitis B Vaccines · multiple reported outcomes

34 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 30benefit: 3null: 1

PMID 42330006 PMID 41448530 PMID 41935745 PMID 42170843 PMID 39820185 PMID 41865748 PMID 35049430 PMID 20819147 PMID 41267335 PMID 41555034

higher-confidence evidence

Hepatitis B Surface Antigens · multiple reported outcomes

29 studies

Status: apparently conflicting; different clinical questions. Population: HBsAg. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 25harm: 2null: 2

PMID 41219059 PMID 41623121 PMID 42287020 PMID 41427832 PMID 41390946 PMID 41721875 PMID 35592651 PMID 37459311 PMID 42479941 PMID 42069606

higher-confidence evidence

Antiviral Agents · multiple reported outcomes

14 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B; HBsAg; HBeAg; HBV DNA; ALT. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 9benefit: 1null: 3harm: 1

PMID 37157776 PMID 28427875 PMID 41839198 PMID 42373438 PMID 39528323 PMID 41608776 PMID 42095461 PMID 37442152 PMID 40008890 PMID 38970293

moderate-confidence evidence

tenofovir · multiple reported outcomes

12 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 9null: 1benefit: 1harm: 1

PMID 38805690 PMID 39528324 PMID 40984668 PMID 42076967 PMID 42355610 PMID 41978927 PMID 42424106 PMID 42479363 PMID 42298392 PMID 42453798

higher-confidence evidence

Antiviral Agents · multiple reported outcomes

12 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B; HBsAg; HBV DNA. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 10benefit: 1null: 1

PMID 41854418 PMID 40528088 PMID 39988055 PMID 42206582 PMID 40953786 PMID 37393402 PMID 41942346 PMID 42405762 PMID 42470636 PMID 42328176

higher-confidence evidence

Hepatitis B Antibodies · multiple reported outcomes

12 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 10benefit: 1null: 1

PMID 41448530 PMID 41992416 PMID 20819147 PMID 41267335 PMID 41622674 PMID 42043261 PMID 39819251 PMID 39770341 PMID 42538702 PMID 41838860

higher-confidence evidence

DNA, Viral · multiple reported outcomes

11 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B; HBsAg; HBeAg; HBV DNA; ALT. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 7benefit: 1null: 3

PMID 37157776 PMID 41839198 PMID 42373438 PMID 39528323 PMID 41608776 PMID 42095461 PMID 37442152 PMID 40008890 PMID 38970293 PMID 35941076

moderate-confidence evidence

DNA, Viral · multiple reported outcomes

9 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B; HBV DNA. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 7benefit: 1null: 1

PMID 19399801 PMID 39828249 PMID 39373164 PMID 41412547 PMID 42226728 PMID 42003011 PMID 42503913 PMID 40431695 PMID 40996243

moderate-confidence evidence

tenofovir disoproxil fumarate · multiple reported outcomes

9 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 6null: 1benefit: 1harm: 1

PMID 38805690 PMID 39528324 PMID 40984668 PMID 42355610 PMID 41978927 PMID 42424106 PMID 42479363 PMID 42298392 PMID 42359468

moderate-confidence evidence

entecavir · multiple reported outcomes

8 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 6null: 1benefit: 1

PMID 41138575 PMID 37400385 PMID 42076967 PMID 42424106 PMID 42479363 PMID 42578184 PMID 42291993 PMID 41798742

limited evidence

tenofovir alafenamide · multiple reported outcomes

8 studies

Status: apparently conflicting; different clinical questions. Population: chronic hepatitis B. Comparator: multiple or inconsistently reported comparators.

The records use different or inconsistently reported comparators.
The records report different endpoints or outcome definitions.
The evidence combines different study designs.
Some abstracts do not state whether the primary endpoint was met.

unknown: 6null: 1harm: 1

PMID 38805690 PMID 42076967 PMID 41978927 PMID 42424106 PMID 42479363 PMID 42298392 PMID 42453798 PMID 42359468

Failed or Negative Trials

Hepatitis B virus (HBV) revaccination in MSM who were born in the nationwide neonatal HBV vaccination era: A randomized clinical trial.

randomized controlled trial · 2026 · PMID 41448530

Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trial.

randomized controlled trial · 2025 · PMID 39988055

PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial.

randomized controlled trial · 2025 · PMID 39094743

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

randomized controlled trial · 2025 · PMID 41335575

Comprehensive Interventions in HBV Care: Nursing-Sensitive Approach.

randomized controlled trial · 2025 · PMID 39820185

Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.

randomized controlled trial · 2024 · PMID 39327857

Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

randomized controlled trial · 2026 · PMID 41757470

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.

randomized controlled trial · 2026 · PMID 42150672

Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial.

randomized controlled trial · 2026 · PMID 40953786

Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.

randomized controlled trial · 2024 · PMID 37561058

Emerging and Experimental Research

Interventions to Increase Hepatitis B Testing Uptake Amongst Detained Populations: A Systematic Review.

meta analysis · 2026 · PMID 42163587

[Clinical study on the efficacy of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia patients with chronic hepatitis B].

randomized controlled trial · 2026 · PMID 42373438

The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial.

randomized controlled trial · 2026 · PMID 42173110

A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants.

randomized controlled trial · 2026 · PMID 41085094

ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial.

randomized controlled trial · 2026 · PMID 41554267

Safety and efficacy of tenofovir alafenamide in preventing hepatitis B virus recurrence after liver transplantation in patients with chronic kidney disease maintained on tenofovir disoproxil fumarate: Results from a phase 2 randomized trial.

randomized controlled trial · 2026 · PMID 40972902

Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis B.

randomized controlled trial · 2026 · PMID 42163628

VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial.

randomized controlled trial · 2026 · PMID 42214405

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

randomized controlled trial · 2026 · PMID 41203919

Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controlled Trial (SPHERE) Protocol.

randomized controlled trial · 2026 · PMID 42176181

Evidence Gaps

Detailed risk-of-bias assessment remains limited

PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.

Complete Ranked PubMed Index

The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.

Current Standard Of Care60 records

Rank114.5

Clinical guideline or consensus statement

The APLAR Recommendations for the Management of Psoriatic Arthritis.

International journal of rheumatic diseases · 2025 · PMID 40725984

Rank112.0

Clinical guideline or consensus statement

Gastroenterology · 2026 · PMID 42017860

Rank110.0

Clinical guideline or consensus statement

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

Journal of hepatology · 2025 · PMID 40348683

The updated EASL Clinical Practice Guidelines on the management of hepatitis B virus (HBV) infection provide comprehensive, evidence-based recommendations for its management. Spanning ten thematic sections, the guidelines address diagnostics, treatment goals, treatment indications, therapeutic options, hepatocellular carcinoma surveillance, management of special populations, HBV reactivation prophylaxis, post-transplant care, HBV prevention strategies, and finally address open questions and future research directio…

Rank110.0

Clinical guideline or consensus statement

[Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · 2026 · PMID 42236454

Rank110.0

Clinical guideline or consensus statementResult signal: harm

Brazilian Society of Rheumatology - 2025 recommendations on vaccination in immune-mediated rheumatic diseases.

Advances in rheumatology (London, England) · 2026 · PMID 41578353

Rank110.0

Clinical guideline or consensus statement

[Interpretation of key updates of the 2026 version of the APASL clinical practice guidelines for the management of chronic hepatitis B].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026 · PMID 42706035

The Asia-Pacific region has the heavy burden of chronic hepatitis B. In 2026, the Asia-Pacific Association for the Study of the Liver (APASL) updated its clinical practice guidelines for the management of chronic hepatitis B. The recommendations in this version of the guideline are formulated around focusing 13 core areas: vaccination and universal screening strategies, an established system of progressive treatment goals, pathways for stratified assessment of liver fibrosis based on resource availability, expansio…

Rank110.0

Clinical guideline or consensus statement

British Association of Sexual Health and HIV guidelines on the management of viral hepatitis 2026.

International journal of STD & AIDS · 2026 · PMID 42117446

Rank110.0

Clinical guideline or consensus statement

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine · 2026 · PMID 40197438

Rank110.0

Clinical guideline or consensus statement

APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.

Hepatology international · 2026 · PMID 42365189

Globally, especially in the Asia Pacific region, chronic hepatitis B infection has led to an undesirable escalating morbidity and mortality with acute-on chronic liver failure, end-staged liver cirrhosis, and hepatocellular carcinoma. This has happened despite the past four decades of major scientific advances made in screening methods, vaccination strategies, highly effective low-cost anti-viral therapies, and surveillance strategies for early detection of hepatocellular carcinoma. To address this health threat, A…

Rank110.0

Clinical guideline or consensus statement

[Chinese expert consensus on clinical practice of chronic hepatitis B functional (clinical) cure].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025 · PMID 41167769

Chronic hepatitis B functional (clinical) cure is currently an important therapeutic endpoint, which significantly reduces the incidence risk of cirrhosis and liver cancer. This expert consensus focuses on key clinical issues on the basis of previous studies, systematically elaborates population stratification and stepwise treatment strategies based on patient characteristics, consolidation therapy, relapse management, long-term monitoring after serum HBsAg clearance, and optimal management for patients who have no…

Rank110.0

Clinical guideline or consensus statement

Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations.

The Medical journal of Australia · 2025 · PMID 40976940

INTRODUCTION: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, the sixth most common cause of cancer death in Australia. With shifting aetiologies and a growing at-risk population, consistent routine surveillance recommendations are key to early detection of HCC and improved survival. We developed new evidence-based HCC surveillance guidelines for people at high risk in Australia due to liver disease and/or other risk factors. These guidelines were developed by a working group of expe…

Rank107.0

Systematic review or meta-analysis

Serum chloride concentrations and outcomes in adult patients with cirrhosis: a systematic review and meta-analysis.

BMC nephrology · 2025 · PMID 41013381

PURPOSE: Electrolyte disturbances, including hyponatremia, are common in cirrhosis, with hyponatremia already incorporated into the MELD-Na score as a prognostic marker. However, the prognostic role of serum chloride, the main extracellular anion, remains underexplored. Emerging evidence suggests hypochloremia is independently associated with increased mortality and acute kidney injury (AKI) in cirrhotic patients. Proposed mechanisms include dysregulated activation of the renin-angiotensin, vasopressin, and sympath…

Rank102.6

Systematic review or meta-analysis

Evaluating Infections in Solid Organ Donors Before Transplantation: A Systematic Review of Clinical Practice Guidelines.

Transplantation · 2026 · PMID 41805905

BACKGROUND: Donor-derived infection remains a risk in solid organ transplantation. Clinical practice guidelines inform best practices for donor evaluation and acceptance, although they vary across centers and regions. This study aimed to evaluate the quality and consistency of guidelines for the evaluation of infections in solid organ donors and to summarize their recommendations. METHODS: We searched electronic databases and websites of professional organizations for clinical practice guidelines and consensus stat…

Rank102.0

Systematic review or meta-analysis

Identifying barriers and facilitators to accessing harm reduction services in prisons: A systematic narrative synthesis.

The International journal on drug policy · 2025 · PMID 40517606

BACKGROUND: Drug use is prevalent in carceral settings globally. Although a comprehensive harm reduction package for people in prison (PIP) is recommended by international agencies, its implementation is limited. The aim of this systematic narrative synthesis was to explore barriers and facilitators to accessing harm reduction services (HRS) in prisons. METHODS: We searched MEDLINE, PsycINFO, SCOPUS, and CINAHL for English and French language articles published before June 26, 2024. Studies evaluating any HRS defin…

Rank100.0

Systematic review or meta-analysis

Economic evaluation of hepatitis B screening in low- and middle-income countries: a systematic review.

International journal of clinical pharmacy · 2025 · PMID 40982118

INTRODUCTION: Hepatitis B virus (HBV) causes significant morbidity and mortality worldwide, particularly in low- and middle-income countries (LMICs) with intermediate to high endemicity. Screening interventions are essential for reducing infection rates. AIM: To synthesize economic evaluation evidence of hepatitis B (HBV) screening strategies in LMICs. METHOD: A comprehensive search of PubMed, Embase, and Scopus was conducted up to August 08, 2024. All types of economic evaluations comparing HBV screening strategie…

Rank96.0

Systematic review or meta-analysis

Risk of hepatitis B virus reactivation associated with interleukin inhibitor therapies: protocol for a systematic review and meta-analysis.

BMJ open · 2025 · PMID 41213667

INTRODUCTION: The widespread application of interleukin (IL) inhibitors for various conditions, including gastrointestinal, rheumatologic, dermatologic and pulmonary diseases, has raised concerns regarding the potential for hepatitis B virus reactivation (HBVr). However, the precise risk of HBVr remains unclear due to inconsistencies in existing research. This systematic review aims to quantify the risk of HBVr in patients receiving IL inhibitor therapies. METHODS AND ANALYSIS: This systematic review will follow Pr…

Rank87.0

Randomized clinical study

Advances in the management of hepatitis B.

BMJ (Clinical research ed.) · 2025 · PMID 40461178

Hepatitis B virus infection remains a pervasive global health challenge, affecting an estimated 254 million people worldwide. This review summarizes the current landscape of hepatitis B, including its epidemiology and the clinical spectrum of acute and chronic infection. It discusses the interplay between host and virus that underlies the progression from acute hepatitis to chronic liver disease, cirrhosis, and hepatocellular carcinoma. The review further examines current screening practices, diagnostic methods, an…

Rank50.2

Other PubMed-indexed publication

[Characteristics and predictive factors of recompensation in patients with hepatitis B-related decompensated cirrhosis: a retrospective cohort study].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026 · PMID 42706038

Objective: To investigate and evaluate the incidence rate, time distribution, related factors, and prediction model discriminative ability for recompensation in patients with hepatitis B-related decompensated cirrhosis. Methods: Four hundred and five patients hospitalized for the first time due to hepatitis B-related decompensated cirrhosis were retrospectively enrolled, using the date of initial hospitalization for decompensation as the follow-up initial point. Recompensation was defined as the resolution conditio…

Rank50.0

Other PubMed-indexed publication

[Clinical outcomes of small-size grafts in auxiliary liver transplantation for the treatment of portal hypertension].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025 · PMID 41355128

Objective: To evaluate the safety and efficacy of using small and ultra-small sized grafts for in situ auxiliary liver transplantation in the treatment of portal hypertension. Methods: A prospective single-arm cohort study was conducted. Patients who underwent liver transplantation at Beijing Friendship Hospital from December 2014 to July 2025 were included. Intraoperative portal vein pressure was routinely monitored, with the target regulation for portal vein blood flow set at<15 mmHg (1 mmHg=0.133 kPa) and follow…

Diagnosis And Screening60 records

Rank110.0

Clinical guideline or consensus statement

Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensus.

Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026 · PMID 42615769

Rank94.7

Randomized controlled trial

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

Journal of hepatology · 2026 · PMID 42142631

BACKGROUND & AIMS: HDV requires HBsAg for viral assembly. The siRNA JNJ-73763989 (JNJ-3989) targets all HBV transcripts and reduces HBsAg in patients with chronic hepatitis B. We evaluated whether HBsAg reduction with JNJ-3989 leads to a decline in HDV RNA and ALT in patients with chronic hepatitis D (CHD). METHODS: REEF-D, a two-part, phase II, randomized, double-blind, placebo-controlled study, enrolled 22 adults with CHD in Part 1. Participants were randomized 4:1 to receive JNJ-3989 (100 mg subcutaneously every…

Rank68.4

Prospective cohort study

HBsAg isoforms predict HBsAg seroclearance and finite treatment in patients with chronic hepatitis B after cessation of long term nucleos(t)ide analogue.

JHEP reports : innovation in hepatology · 2026 · PMID 42562264

BACKGROUND AND AIMS: We examined the role of HBsAg isoforms to predict HBsAg seroclearance or finite treatment among patients with chronic hepatitis B (CHB) infection who stopped long-term nucleoside analogue (NUC). METHODS: This prospective study recruited patients with HBeAg-negative non-cirrhotic CHB on ≥3 years of first-line NUC with NUC cessation. NUC was resumed upon clinical relapse (CR) or major virological rebound (mVR). HBV biomarkers were measured at baseline, CR or mVR (if any), and end-of-follow-up. Th…

Rank66.1

Observational or cohort study

Evaluating the risk: Hepatitis B virus reactivation in ocrelizumab-treated patients with multiple sclerosis: A single-center experience and review of the literature.

Multiple sclerosis and related disorders · 2026 · PMID 42431141

BACKGROUND: Ocrelizumab is a highly effective anti-CD20 monoclonal antibody used in the treatment of multiple sclerosis (MS). However, B-cell depletion may increase the risk of hepatitis B virus (HBV) reactivation, particularly in patients with previous HBV exposure. Real-world data regarding this risk in patients receiving ocrelizumab remain limited. METHODS: We conducted a retrospective observational cohort study including adult patients with MS who received ocrelizumab between January 2018 and December 2025 at a…

Rank60.0

Observational or cohort study

Seroprevalence of hepatitis D among hepatitis B-infected patients attending the viral hepatitis treatment unit in Alexandria, Egypt: a prospective cross-sectional observational study.

BMC infectious diseases · 2026 · PMID 42608674

BACKGROUND: Hepatitis D virus (HDV) infection accelerates liver illness progression in hepatitis B surface antigen (HBsAg)-positive individuals, yet its prevalence in Alexandria, Egypt, is unknown. METHODS: We carried out a prospective cross-sectional observational study on 158 HBsAg-positive adults attending the Alexandria University Viral Hepatitis Treatment Unit (Sept 2022-Aug 2023). All underwent clinical, laboratory, and imaging assessment, and serum total anti-HDV antibodies were detected by ELISA. RESULTS: A…

Rank56.6

Other PubMed-indexed publication

Development and validation of GADA model for diagnosing hepatocellular carcinoma in Chinese hepatitis B patients.

Chinese medical journal · 2026 · PMID 42608650

BACKGROUND: Chronic hepatitis B virus (HBV) infection accounts for more than 40% of hepatocellular carcinoma (HCC) cases worldwide. The GALAD (Gender, Age, alpha fetoprotein heterogeneity [AFP-L3], AFP, and des-gamma-carboxy prothrombin [PIVKA-II/DCP]) model has potential for enhancing HCC diagnosis. However, its diagnostic performance in HBV-associated chronic liver disease requires further optimization. This study aimed to establish a diagnostic model for HBV-associated HCC. METHODS: The data from 2190 patients w…

Rank54.5

Other PubMed-indexed publication

Metabolomic machine learning predictor for the diagnosis of alcohol-associated liver disease.

Clinica chimica acta; international journal of clinical chemistry · 2026 · PMID 42259427

BACKGROUND: It is urgent to find novel non-invasive biomarkers that can accurately diagnose alcohol-associated liver disease (ALD). The objective of this study was to explore dysregulated metabolites in the serum of ALD patients by metabolomics, and establish a reliable diagnostic model by machine learning algorithms. METHODS: A total of 1800 participants, including ALD, metabolic dysfunction-associated steatotic liver disease (MASLD), chronic hepatitis B (CHB), alcohol use disorder (AUD) and normal control (NC) in…

Rank54.4

Other PubMed-indexed publication

Under-vaccination as a systems failure: A Monte Carlo simulation of the 2025 CDC/ACIP hepatitis B birth-dose policy shift and multi-level intervention packages, 2025-2035.

Vaccine · 2026 · PMID 42365679

BACKGROUND: In 2025, the CDC/ACIP reclassified the hepatitis B (HBV) birth-dose recommendation from universal vaccination to a shared clinical decision-making (SCDM) model. U.S. adult HBV vaccination rates remain stagnant at 30-32%, reflecting systemic delivery failures. The projected impact of this policy shift and whether multi-level interventions can protect vulnerable populations remains unquantified. METHODS: We developed a Monte Carlo simulation (N = 50,000 iterations) projecting U.S. vaccination outcomes fro…

Rank54.0

Other PubMed-indexed publication

Decoding Tumor Heterogeneity with Imaging Biomarkers Predicts Microvascular Invasion and Postoperative Risk Stratification in Hepatocellular Carcinoma.

Academic radiology · 2026 · PMID 42586894

RATIONALE AND OBJECTIVES: Microvascular invasion (MVI) is a major driver of recurrence and poor outcomes in hepatocellular carcinoma (HCC), yet biopsy-based pathologic assessment is invasive and susceptible to sampling bias and delayed availability. We aimed to develop and validate a noninvasive preoperative model integrating multiphase magnetic resonance imaging-derived habitat/intratumoral heterogeneity (ITH) features and clinical variables for MVI prediction and postoperative recurrence-risk stratification. METH…

Rank53.4

Other PubMed-indexed publication

Prevalence and predictive factors of chronic kidney disease among individuals with cardiometabolic risk factors: A multicenter cross-sectional study, North East Ethiopia.

Clinical medicine (London, England) · 2026 · PMID 42398670

BACKGROUND: Chronic kidney disease (CKD) is a major global public health concern, affecting more than 9% of adults worldwide and contributing to rising morbidity, mortality, and healthcare costs. The burden is disproportionately higher in low-resource settings such as Sub-Saharan Africa, where limited diagnostic capacity leads to delayed detection and accelerated progression to kidney failure. In Ethiopia, existing evidence is largely confined to diabetic populations, with minimal data on other high-risk groups. Th…

Rank53.0

Other PubMed-indexed publication

Hepatitis B and D burden in Uzbekistan: comprehensive analysis of seroprevalence and risk correlates from a countrywide study.

Infectious diseases of poverty · 2026 · PMID 42608708

BACKGROUND: Uzbekistan faces a substantial burden of hepatitis B and D virus (HBV and HDV) infections despite implementing universal hepatitis B vaccination in 1998. Regional variation in disease distribution and contemporary transmission dynamics remain inadequately characterized. Our objective was to evaluate the geographically stratified prevalence of HBV and HDV, while also identifying the key risk factors fueling transmission within the adult population of Uzbekistan. METHODS: We conducted a nationwide cross-s…

Rank52.5

Other PubMed-indexed publication

Preoperative gut microbiota combined with machine learning for predicting post-hepatectomy liver failure in HBV-related hepatocellular carcinoma: a pilot study.

Frontiers in cellular and infection microbiology · 2026 · PMID 42625750

OBJECTIVE: This study investigated the association between preoperative gut microbiota (GM) profiles and post-hepatectomy liver failure (PHLF) in patients with newly diagnosed HBV-related hepatocellular carcinoma (HBV-HCC), aiming to explore non-invasive, modifiable GM biomarkers for perioperative risk stratification. METHODS: A total of 233 fecal samples underwent 16S rRNA sequencing and were stratified into three distinct sets: a training set (n = 179), an internal validation set (n = 32), and an independent exte…

Rank51.7

Other PubMed-indexed publication

Self-reported hepatitis B diagnoses and vaccination history in trans and non-binary communities in Germany, the TASG-study* 2022.

BMC public health · 2026 · PMID 42576212

BACKGROUND: In Germany, little is known about hepatitis B (HepB) prevalence and vaccination coverage among transgender and non-binary people (TNBP), a WHO-defined viral hepatitis key population. Our study aimed to assess self-reported HepB diagnoses, self-reported positive vaccination history, and potential predictors for a positive vaccination history in a subset of participants for whom the German standing committee on vaccination recommend HepB vaccination. METHODS: We analysed data from a 2022 cross-sectional o…

Rank50.7

Other PubMed-indexed publicationResult signal: null

Diagnosis of Small Focal Liver Lesions (≤2 cm): A Deep Learning Approach Based on B-Mode Ultrasound and Contrast-Enhanced Ultrasound.

Ultrasound in medicine & biology · 2026 · PMID 42350195

BACKGROUND: To develop and validate a deep learning (DL) model based on feature fusion with B-mode ultrasound (BMUS) and contrast enhanced ultrasound (CEUS) images for non-invasive diagnosis of benign and malignant focal liver lesions (FLLs), especially for small FLLs (≤2.0 cm). METHODS: A retrospective dataset of 687 patients who were diagnosed with FLLs by BMUS and underwent CEUS between September 2016 and March 2020 was collected in this study. The dataset was divided into a training set (80%) and a test set (20…

Rank50.1

Other PubMed-indexed publication

Metagenomic sequencing detects viruses and bacteria in a cross-sectional clinical cohort of undifferentiated febrile illness in Nigeria.

mSphere · 2026 · PMID 42584108

UNLABELLED: Molecular and microscopy-based diagnostic capacity is often insufficient or unavailable in places where infectious disease burdens are highest, such as in West Africa. Rapid diagnostic testing (RDT) can provide quick and affordable diagnoses of common infections but is an imperfect solution due to limitations around detecting and dealing with false-negative and false-positive results. An alternative to RDT is unbiased metagenomic sequencing for pathogen surveillance. Here, we present data from unbiased …

Rank49.7

Other PubMed-indexed publication

Red cell distribution width-to-platelet ratio (RPR) as a simple non-invasive predictor of liver cirrhosis in patients with chronic hepatitis B: a cross-sectional study.

Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina · 2026 · PMID 42593001

AIM: Chronic hepatitis B (CHB) is a major cause of liver cirrhosis worldwide. This study aimed to evaluate the red cell distribution width-to-platelet ratio (RPR) as a simple non-invasive predictor of cirrhosis in CHB patients. METHODS: A cross-sectional study was conducted in 221 CHB patients at H. Adam Malik General Hospital, Medan, Indonesia (May 2024-May 2025). Cirrhosis was diagnosed by FibroScan (≥ 14 kPa) or ultrasonography findings. RPR was calculated from routine haematology data. Bivariate analysis was us…

Rank49.5

Other PubMed-indexed publication

Association of week-12 HBsAg Decline with HBsAg Clearance in Patients with Hepatitis B-Related Cirrhosis Receiving Pegylated Interferon Combined with Nucleos(T)ide Analogue Therapy: A Retrospective Cohort Study.

International journal of general medicine · 2026 · PMID 42583160

PURPOSE: This study aimed to evaluate the association between the relative decline rate of HBsAg at week 12 (HBsAg R) and achieving HBsAg clearance in patients with compensated HBV-related cirrhosis. PATIENTS AND METHODS: This study included 174 patients with compensated hepatitis B-related cirrhosis receiving pegylated interferon-alpha and nucleos(t)ide analogue therapy. HBsAgR was defined as (week-12 HBsAg - baseline HBsAg) / baseline HBsAg, where a more negative value indicates greater decline. To identify stabl…

Rank49.4

Other PubMed-indexed publication

Comparative analysis of biomarker profiles in chronic kidney disease with and without hepatitis B co-infection in Iraq.

Computational biology and chemistry · 2026 · PMID 42070332

BACKGROUND: Chronic kidney disease (CKD) and hepatitis B virus (HBV) infection are major health challenges. While both individually disrupt systemic homeostasis, their potential synergistic effects on hematological, lipid, and renal function profiles remain poorly defined in specific demographics. OBJECTIVE: This study aims to comparatively analyze key hematological, lipid, and renal function biomarkers among Iraqi CKD patients with HBV co-infection, CKD patients without HBV, and healthy controls. METHODS: A cross-…

Rank49.3

Other PubMed-indexed publication

Serum HBV RNA reflects persistent viral transcriptional activity in nucleos(t)ide analogue-treated patients despite suppressed HBV DNA.

Diagnostic microbiology and infectious disease · 2026 · PMID 42365785

BACKGROUND: Accurate assessment of viral transcriptional activity remains challenging in chronic hepatitis B (HBV) infection, especially in patients with suppressed HBV DNA. Serum HBV RNA has emerged as a potential biomarker reflecting covalently closed circular DNA (cccDNA) activity. METHODS: A total of 336 HBV-infected patients, including chronic hepatitis B (CHB, n = 67), liver cirrhosis (LC, n = 149), and hepatocellular carcinoma (HCC, n = 120), were retrospectively enrolled. Serum HBV RNA, HBV DNA, serological…

Rank49.1

Other PubMed-indexed publication

Change in Two-Dimensional Shear Wave Elastography: A New Predictor of Hepatitis B-Related HCC Progression After Ablation.

Ultrasound in medicine & biology · 2026 · PMID 42420054

OBJECTIVE: Ablation is an important therapy for hepatocellular carcinoma (HCC). This study aims to explore the changes in pre- and short-term-post-ablative two-dimensional shear wave elastography (2D-SWE) measurements and assess the feasibility of using pre- and short-term-post-ablative indicators, including 2D-SWE measurements, to predict HCC progression after curative ablation. METHODS: A total of 161 treatment-naïve chronic hepatitis B-related HCC patients were divided into training (n = 107) and validation (n =…

Rank48.6

Other PubMed-indexed publication

Therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg for HBV/HDV co-infection.

JHEP reports : innovation in hepatology · 2026 · PMID 42607868

BACKGROUND & AIMS: Achieving functional cure for chronic hepatitis B (CHB) will likely require a combinatorial approach targeting multiple aspects of the complex hepatitis B virus (HBV) life cycle and host adaptive immune responses. Here, we developed a therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg, required for cellular entry of both hepatitis B and D viruses. METHODS: An established potent T-cell inducing platform, recombinant adenovirus (Ad), was used as a nanoparticle scaffold for PreS1…

Rank48.4

Other PubMed-indexed publication

A prospective evaluation of Cepheid Xpert® and Roche cobas® HIV-1, HBV and HCV assays for nucleic acid quantification.

Diagnostic microbiology and infectious disease · 2026 · PMID 42184582

BACKGROUND: Quantification of HBV DNA, HIV and HCV RNA allows monitoring of disease progression and management. An easy-to-use cartridge-based real-time polymerase chain reaction (PCR) assay for quantification of HIV, HBV and HCV can provide supplementary benefits, for example, in low resource settings instead of large, automated PCR systems. Our aim was to assess interassay agreement between Cepheid Xpert HIV-1 Viral Load XC, HBV Viral Load and HCV Viral Load, and Roche cobas HIV-1, HBV and HCV assays with routine…

Rank48.2

Other PubMed-indexed publication

Comparative evaluation of noncontrast computed tomography (CT) histogram analysis, FibroScan, and serum markers for liver fibrosis assessment in chronic hepatitis B patients.

Clinical radiology · 2026 · PMID 42501700

AIM: This study aimed to evaluate the relationship between noncontrast computed tomography (CT) histogram analysis and biopsy-based fibrosis staging, FibroScan, and serum-based scoring systems in patients with chronic hepatitis B. MATERIALS AND METHODS: In 40 patients with histopathologically staged fibrosis, histogram parameters derived from noncontrast CT images were compared with FibroScan measurements and aspartate aminotransferase-to-platelet ratio index (APRI)/Fibrosis-4 (FIB-4) scores. Correlation analyses w…

Rank45.0

Other PubMed-indexed publication

Personal and family application of cancer prevention practices among physicians.

Scientific reports · 2026 · PMID 42613360

Healthcare providers play a pivotal role in cancer prevention through screening advocacy, lifestyle counseling, and risk communication. However, limited evidence exists on whether physicians apply these preventive practices to themselves and their families. This study assessed personal and family-oriented cancer prevention behaviors among physicians and explored behavioral determinants using the Health Belief Model (HBM), with particular attention to differences between oncology-related and non-oncology specialties…

Rank45.0

Other PubMed-indexed publication

A light-activated one-pot ERA/CRISPR-Cas12a assay for cost-effective dual-mode detection of HBV DNA.

Talanta · 2026 · PMID 42557140

Light-activatable CRISPR-Cas systems offer an effective strategy to overcome the kinetic incompatibility in one-pot nucleic acid assays; however, their practical application remains limited by high reagent cost, the lack of compatible reaction buffers, and reliance on instrument-dependent readout. In this work, we developed a cost-effective light-controlled one-pot ERA/CRISPR-Cas12a platform for rapid hepatitis B virus (HBV) DNA detection. NPOM-caged crRNA was employed to temporarily suppress Cas12a activity during…

Evidence Syntheses60 records

Rank110.0

Systematic review or meta-analysis

An umbrella review navigating the nationwide burden of hepatitis B virus infection in Ethiopia: A call for action on vaccination, safe blood, and infection prevention.

PloS one · 2026 · PMID 42330006

Journal of epidemiology and global health · 2026 · PMID 41996018

Mauritania has a high prevalence of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV), posing a major public health burden. A comprehensive analysis of seroprevalence, transmission dynamics, and molecular epidemiology would help inform strategies for public health interventions. This study systematically reviews the published literature in the field between 1983 and 2024, employing PRISMA 2020 guidelines. Where insufficient data were available for meta-analyses on specific inquiries, summative description…

Rank108.5

Systematic review or meta-analysis

The incidence of spontaneous HBsAg loss in patients with different baseline HBsAg levels: a systematic review and meta-analysis.

Hepatology international · 2026 · PMID 41686332

BACKGROUND AND AIMS: Hepatitis B surface antigen (HBsAg) seroclearance is an ideal treatment end point in chronic hepatitis B (CHB), linked to improved clinical outcomes. Baseline HBsAg level is a key predictor, but pooled evidence on the annual incidence of spontaneous HBsAg clearance in untreated CHB patients, stratified by baseline HBsAg levels, is lacking. We conducted a systematic review and meta-analysis to quantify this incidence. METHODS: Six databases were searched for cohort studies and randomized trials …

Rank108.3

Systematic review or meta-analysis

Efficacy and safety of clipping prior to cyanoacrylate embolization in gastric varices: a single-arm systematic review and meta-analysis.

Surgical endoscopy · 2026 · PMID 42377512

BACKGROUND: Gastric variceal bleeding is a life-threatening complication of portal hypertension. Cyanoacrylate injection is the standard endoscopic treatment that carries a significant risk of ectopic embolization, particularly in patients with gastrorenal shunts. Adding endoscopic clips before injection may enhance safety and efficacy, yet evidence remains limited. This study evaluates the safety and effectiveness of clip-assisted cyanoacrylate injection (clip-ECI). METHODOLOGY: A systematic search was conducted o…

Rank108.0

Systematic review or meta-analysis

Clinicopathological significance of Gli1 expression in hepatocellular carcinoma: a meta-analysis.

Scientific reports · 2026 · PMID 41968128

This meta-analysis assessed the clinicopathological significance of GLI1 in hepatocellular carcinoma (HCC). We systematically searched PubMed, Web of Science, Embase, Cochrane Library, Wan Fang, and CNKI for studies through October 2025. Studies assessing GLI1 by immunohistochemistry in HCC tissue and reporting its clinicopathological correlations were included. Study quality was evaluated using the Newcastle-Ottawa Scale. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Publication bia…

Rank107.7

Systematic review or meta-analysisResult signal: benefit

First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety.

Frontiers in immunology · 2026 · PMID 42220514

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the front-line treatment of advanced hepatocellular carcinoma (HCC). However, the comparative efficacy and safety of different ICI-based regimens-and their consistency across etiologic subgroups [HBV, HCV, and non-HBV/non-HCV (NBNC)]-remain uncertain. This study conducted a Bayesian network meta-analysis (NMA) of recent randomized controlled trials (RCTs) to compare the first-line immunotherapy strategies both overall and by viral etiology. METHODS…

Rank107.5

Systematic review or meta-analysis

Effectiveness of Digital Health Interventions to Improve Self-Care in Patients With Chronic Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of medical Internet research · 2026 · PMID 42263266

BACKGROUND: Chronic diseases account for most global morbidity and mortality, increasing the need for effective long-term self-care support. Digital health interventions, such as mobile apps, telemonitoring, and connected devices, are increasingly used to promote self-care; yet, their overall effectiveness across chronic conditions remains unclear. OBJECTIVE: This systematic review and meta-analysis evaluated whether digital health interventions improve self-care in adults with chronic diseases. METHODS: We searche…

Rank107.3

Systematic review or meta-analysis

Viral hepatitis co-infections with tuberculosis in India: A systematic review and meta-analysis.

The Indian journal of medical research · 2026 · PMID 42295712

Background and objectives Tuberculosis (TB) and viral hepatitis (hepatitis B and C) co-infection is a significant threat in low-and middle-income countries like India. To optimise treatment protocols and prevent liver-related complications, it is essential to estimate the burden of these co-infections. This systematic review and meta-analysis were conducted to determine the prevalence of hepatitis B and C co-infection with tuberculosis in India. Methods In line with PRISMA guidelines, a systematic search of PubMed,…

Rank106.7

Systematic review or meta-analysisResult signal: benefit

Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis.

BMC infectious diseases · 2026 · PMID 42288778

OBJECTIVE: To evaluate the efficacy and safety of antiretroviral therapy(ART) regimens based on tenofovir(TDF) + lamivudine(3TC) + efavirenz(EFV) in patients co-infected with Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV), thereby providing evidence-based support for clinical treatment decision-making. METHODS: Relevant studies published from database inception to March 2025 were systematically retrieved from the CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, Web of Science, and Cochrane Library datab…

Rank106.0

Systematic review or meta-analysis

Thymosin-ɑ1 for people with chronic hepatitis B.

The Cochrane database of systematic reviews · 2026 · PMID 42713852

RATIONALE: Chronic hepatitis B is a global public health concern. It is caused by infection with the hepatitis B virus (HBV). The goal of treating chronic HBV infection is to prevent progression to chronic hepatitis, cirrhosis, hepatic decompensation, liver failure, hepatocellular carcinoma, and death. Individual studies have evaluated various immunomodulatory therapies with inconsistent results. Thymosin-ɑ1 is known to have antiviral effects; however, results of randomised clinical trials on the effects of thymosi…

Rank105.9

Systematic review or meta-analysis

Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis.

Liver international : official journal of the International Association for the Study of the Liver · 2026 · PMID 42287020

BACKGROUND AND AIMS: This study aimed to determine the incidence of hepatitis B virus reactivation (HBVr) in patients with chronic or occult HBV infection who were treated with IL-12/23, IL-23 (together referred to as anti-IL-23/12), IL-17, or JAK inhibitors without antiviral prophylaxis. In addition, we sought to assess whether the risk of HBVr varies according to anti-HBs status among individuals who are anti-HBc positive. METHODS: A systematic review and meta-analysis were conducted in accordance with PRISMA and…

Rank105.5

Systematic review or meta-analysis

HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).

Gut · 2026 · PMID 41198171

BACKGROUND: Peg-interferon (peg-IFN) plays an increasingly important role in HBV cure strategies, either in combination with novel antivirals, as a lead-in or as consolidation treatment. OBJECTIVE: We aimed to provide estimates of hepatitis B surface antigen (HBsAg) decline and clearance that can be achieved with peg-IFN addition to nucleos(t)ide analogue (NA) therapy. DESIGN: This is a post hoc meta-analysis of individual participant data from eight clinical trials involving chronic hepatitis B patients on NA ther…

Rank102.6

Systematic review or meta-analysis

Evaluating Infections in Solid Organ Donors Before Transplantation: A Systematic Review of Clinical Practice Guidelines.

Transplantation · 2026 · PMID 41805905

Rank102.6

Systematic review or meta-analysis

Transmission Risk of Intentional Transplantation of Kidneys From Donors With Active Hepatitis B to Recipients Without Active Hepatitis B: A Systematic Review and Meta-Analysis.

Transplantation · 2026 · PMID 41427832

BACKGROUND: Potential kidney donors with active hepatitis B virus (HBV: positive hepatitis B surface antigen [HBsAg] and/or nucleic acid test [NAT]) are usually declined for HBsAg-negative recipients. Safety may be improved by recipient vaccination and/or antivirals, thereby increasing transplantation opportunities. We quantified HBV transmission risk in this setting to inform donation decisions. METHODS: Systematic review and meta-analysis (MEDLINE, to November 2024) of cohorts comprised of kidney donors with acti…

Rank102.0

Systematic review or meta-analysis

Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review.

The International journal on drug policy · 2026 · PMID 41651702

BACKGROUND: People who are incarcerated experience disproportionately high rates of injecting drug use and infectious disease, including HIV, viral hepatitis and tuberculosis. However, comprehensive global data regarding the availability of services that prevent and manage infectious disease, injecting drug use and related harms remain limited and outdated. We provide the first systematic review to comprehensively examine the availability and coverage of infectious disease prevention, treatment, and harm reduction …

Rank102.0

Systematic review or meta-analysis

The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic review.

Systematic review or meta-analysis

Viral hepatitis co-infections with tuberculosis in India: A systematic review and meta-analysis.

The Indian journal of medical research · 2026 · PMID 42295712

Rank107.0

Clinical guideline or consensus statement

[Guideline for stratified screening and surveillance of primary liver cancer(2020 Edition)].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021 · PMID 33541021

The age-adjusted incidence of primary liver cancer (PLC) has been declining in China. However, PLC cases in China account for 55% globally. The disease burden is still high and the 5-year survival rate was not improved significantly in the past two decades. This guideline outlines PLC screening in the risk populations, both in hospital and community. Liver cirrhosis and chronic hepatitis B are the main causes of PLC in China. For better PLC surveillance and screening in clinical practices, it is recommended to stra…

Rank107.0

Systematic review or meta-analysis

Significant histologic alterations in untreated chronic hepatitis B children: a meta-analysis.

BMC infectious diseases · 2025 · PMID 41233830

BACKGROUND: Chronic hepatitis B (CHB) in children poses a significant public health challenge, yet data on the prevalence of significant liver lesions in this group are limited. METHODS: A comprehensive meta-analysis pooled data on the proportion of significant liver lesions among CHB children. Using the double arcsine transformation and a random-effects model, we combined data on moderate to severe liver inflammation, fibrosis, and cirrhosis. Subgroup analysis and meta-regression were conducted to explore heteroge…

Rank106.9

Systematic review or meta-analysis

Entecavir for children and adults with chronic hepatitis B.

The Cochrane database of systematic reviews · 2025 · PMID 40260837

RATIONALE: Chronic hepatitis B is a major worldwide public health concern. Entecavir, one nucleos(t)ide analogue antiviral therapy option, is recommended as the first-line drug for chronic hepatitis B in many clinical guidelines. However, none of the guideline recommendations are based on the findings of a systematic review with meta-analysis, where entecavir versus no treatment or placebo are compared directly. OBJECTIVES: To evaluate the benefits and harms of entecavir versus no treatment or placebo in children a…

Rank106.7

Systematic review or meta-analysis

Long noncoding RNA small nucleolar RNA host genes as prognostic molecular biomarkers in hepatocellular carcinoma: A meta-analysis.

Cancer medicine · 2024 · PMID 38634194

BACKGROUND: Recently, increasing data have suggested that the lncRNA small nucleolar RNA host genes (SNHGs) were aberrantly expressed in hepatocellular carcinoma (HCC), but the association between the prognosis of HCC and their expression remained unclear. The purpose of this meta-analysis was to determine the prognostic significance of lncRNA SNHGs in HCC. METHODS: We systematically searched Embase, Web of Science, PubMed, and Cochrane Library for eligible articles published up to February 2024. The prognostic sig…

Rank106.4

Systematic review or meta-analysisResult signal: harm

Prevalence and risk factors for key infectious diseases amongst migrants to the UK: a systematic review.

BMC infectious diseases · 2026 · PMID 41776448

BACKGROUND: Migrants are at increased risk of infections including HIV, tuberculosis and viral hepatitis, with poorer outcomes. Early diagnosis and management can reduce morbidity, mortality and onward transmission. This systematic review summarises prevalence of HIV, latent and active tuberculosis and hepatitis B and C among UK migrants and evaluates associated risk factors. METHODS: PubMed/Medline, EMBASE, Web of Science and the Cochrane Library were systematically searched from 2004 to 11 June 2025. The review w…

Rank106.3

Systematic review or meta-analysis

TNF-α Inhibitors and HBV Reactivation Risk in HBsAg-/Anti-HBc+ Patients: A Systematic Review and Meta-Analysis.

Liver international : official journal of the International Association for the Study of the Liver · 2026 · PMID 41623121

BACKGROUND: Tumour necrosis factor-α (TNF-α) inhibitors are integral in the treatment of immune-mediated inflammatory diseases but may precipitate hepatitis B virus reactivation (HBVr) in HBsAg-/anti-HBc+ patients. APASL guidance presumes a greater risk with higher-potency agents, but the evidence is limited and conflicting. We conducted a systematic review and meta-analysis to assess whether TNF-α inhibitor potency alters HBVr risk in HBsAg-/anti-HBc+ individuals and to identify predictors. METHODS: PubMed, Embase…

Rank105.9

Systematic review or meta-analysis

Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis.

Liver international : official journal of the International Association for the Study of the Liver · 2026 · PMID 42287020

Rank105.5

Systematic review or meta-analysis

Association between hepatitis B virus infection and colorectal liver metastasis: a meta-analysis.

Bioengineered · 2021 · PMID 33629626

The paper aims to assess the association between Hepatitis B Virus infection and colorectal liver metastasis by conducting a meta-analysis. The relevant studies were searched until 24 July 2020, Studies that assessed the correlation between HBV infection and CRLM were recruited. A random effects model was applied to calculate the odds ratio (OR) with 95% confidence interval (CI). All data analyses were performed by STATA 12.0 software. Ten studies involving 17529 participants were included in the study. The results…

Rank105.5

Systematic review or meta-analysisResult signal: null

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.

Clinical and molecular hepatology · 2023 · PMID 37157776

BACKGROUND/AIMS: Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and individual patient-level data MA (IPDMA), we compared liver-related outcomes and mortality between CHB-FL and CHB-no FL patients. METHODS: We searched 4 databases from inception to December 2021 and pooled study-level estimates using a random- effects model for conventional MA. For IPDMA, we evaluated outcome…

Rank105.0

Systematic review or meta-analysis

Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis.

The New England journal of medicine · 2026 · PMID 42206582

BACKGROUND: Treatment with bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus (HBV) transcripts, has the potential to result in a functional cure, defined by at least 24 weeks of a sustained HBV DNA level below the lower limit of quantification (LLOQ) and hepatitis B surface antigen (HBsAg) loss after fixed-duration therapy. METHODS: In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcuta…

Rank97.4

Randomized controlled trial

Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · PMID 40953786

BACKGROUND & AIMS: Nucleos(t)ide analogue (NAs) discontinuation promotes hepatitis B surface antigen (HBsAg) clearance among European patients with chronic hepatitis B virus (HBV) infection. The efficacy and safety of a novel HBV biomarker-guided NAs withdrawal strategy among Asian patients was evaluated in this multicenter randomized controlled trial. METHODS: NAs-experienced patients achieving HBsAg <200 IU/mL and undetectable HBV DNA for ≥12 months with HBV RNA or hepatitis core-related antigen undetectable were…

New Research Last 24 Months360 records

Rank110.0

Clinical guideline or consensus statement

Recommendations for the diagnosis of patients with hepatitis delta virus (HDV) in Spain.

Gastroenterologia y hepatologia · 2026 · PMID 42061813

Rank108.2

Systematic review or meta-analysis

Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis.

Frontiers in medicine · 2026 · PMID 42529015

BACKGROUND: Hepatocellular carcinoma (HCC) kills about 830,000 people each year, and most cases arise in chronic viral hepatitis. Better risk markers would let clinicians focus surveillance where it matters. Mac-2 binding protein glycosylation isomer (M2BPGi) is a serum glycobiomarker of liver fibrosis. Several cohort studies tie elevated M2BPGi to HCC. No quantitative synthesis has pooled this evidence across viral etiologies. METHODS: We searched PubMed/MEDLINE, Embase, the Cochrane Library, Web of Science, and S…

Rank106.8

Systematic review or meta-analysis

The efficacy of traditional Chinese medicine on immune function in patients with hepatitis B-related liver fibrosis or cirrhosis: a systematic review and meta-analysis.

Frontiers in medicine · 2026 · PMID 42548801

OBJECTIVE: Currently, there is no effective treatment to reverse hepatitis B-related liver fibrosis or cirrhosis. Current nucleos(t)ide analogs (NAs) control but rarely eliminate hepatitis B virus (HBV), leaving chronic hepatitis B at risk of developing liver fibrosis/cirrhosis. Traditional Chinese medicine (TCM) shows promise in slowing the progression of hepatitis B-related liver fibrosis/cirrhosis, but its impact on immune function remains debated. METHODS: The electronic databases, including Chinese National Kn…

Rank100.0

Systematic review or meta-analysis

Evidence for a relationship between concentrations of nucleos/tide analogue agents and treatment outcome in chronic hepatitis B infection: A systematic review.

The Journal of infection · 2026 · PMID 42419520

Rank100.0

Systematic review or meta-analysisResult signal: harm

Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.

Infectious diseases of poverty · 2026 · PMID 42538553

BACKGROUND: Evidence increasingly shows close, bidirectional links between infectious diseases (IDs) and non-communicable diseases (NCDs). However, research, health policy, and prevention practices still largely address them in separate frameworks. This scoping review summarises the current evidence on the interconnections between IDs and NCDs and explores integrated strategies for their prevention and management. METHODS: This scoping review systematically searched PubMed, Web of Science, and Scopus for English-la…

Rank100.0

Systematic review or meta-analysis

Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis.

The lancet. Gastroenterology & hepatology · 2026 · PMID 41839198

Rank100.0

Systematic review or meta-analysisResult signal: benefit

Efficacy of NAs in combination with Peg-IFN for functional cure in patients with CHB: a meta-analysis of RCTs.

Annals of medicine · 2026 · PMID 41777119

Rank99.5

Randomized controlled trial

AIDS (London, England) · 2026 · PMID 42332911

Occult hepatitis B infection (OBI), defined by the persistence of replication-competent hepatitis B virus (HBV) DNA in the liver in the absence of detectable hepatitis B surface antigen (HBsAg), represents a clinically relevant condition among people with HIV (PWH). The long-term persistence of covalently closed circular DNA within hepatocytes provides the biological basis for potential HBV reactivation, particularly after discontinuations of HBV-active antiretrovirals. In recent years, the increasing use of tenofo…

Rank85.0

Randomized clinical study

A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B.

Hepatology (Baltimore, Md.) · 2026 · PMID 42594347

BACKGROUND AIMS: AHB-137 is a novel ASO targeting a conserved region near the 3' end of all HBV mRNA. This first-in-human phase 1 study evaluated the safety, tolerability, pharmacokinetics (PK), and antiviral efficacy in healthy subjects and chronic hepatitis B (CHB) patients. METHODS: Forty healthy subjects were randomized into four placebo-controlled single ascending dose (100-450 mg, 6:2 AHB-137:placebo) cohorts and one multiple-dose (MD; 300 mg, 6:2) cohort receiving four weekly subcutaneous doses with a Day 4 …

Preclinical Research117 records

Rank100.0

Systematic review or meta-analysis

Chemoprophylaxis effect of EGCG on various digestive system diseases: a systematic review and meta-analysis.

Frontiers in medicine · 2026 · PMID 42359071

BACKGROUND: Epigallocatechin-3-gallate (EGCG) constitutes the main component of tea polyphenols found in tea leaves and has been found to have a positive therapeutic effect on various digestive system diseases. However, no systematic review has been conducted on the research progress and mechanisms of EGCG in relation to digestive system diseases, an its toxicity. METHODS: We conducted a comprehensive literature search for preclinical studies from the inception of each database to 28th September 2025, including Emb…

Rank100.0

Systematic review or meta-analysis

Virus-directed CAR immunotherapies for chronic HBV and HIV: a systematic synthesis of preclinical and early clinical evidences.

Frontiers in medicine · 2026 · PMID 41970383

BACKGROUND: Chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections are among the most important global health issues. Virus-directed CAR-T and CAR-NK are promising strategies capable of targeting virally infected cells. The therapeutic potential, safety, and translational readiness of these platforms have not been fully synthesised. OBJECTIVES: This study assessed preclinical and early clinical evidence of CAR-T and CAR-NK immunotherapies against HBV and HIV, including efficacy, safety an…

Rank100.0

Systematic review or meta-analysisResult signal: harm

The impact of maternal chronic viral hepatitis infections on pregnancy and neonatal outcomes in in vitro fertilization: a systematic review and meta-analysis.

Journal of ovarian research · 2026 · PMID 41840684

BACKGROUND: Chronic hepatitis B (HBV) and hepatitis C (HCV) infections represent a substantial global health burden and increasing numbers of infertile women with chronic HBV/HCV infections seek conception through in vitro fertilization (IVF), raising clinical concerns regarding potential perinatal risks. OBJECTIVE: To investigate the association between maternal viral hepatitis status and pregnancy and neonatal outcomes in IVF populations. METHODS: English-language publications in databases including PubMed, Embas…

Rank88.0

Randomized clinical study

Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients.

Journal of translational internal medicine · 2026 · PMID 41727963

BACKGROUND AND OBJECTIVES: The treatment options for hepatitis B surface antigen (HBsAg) clearance are limited for patients who have failed pegylated interferon-α (Peg-IFNα) therapy. Given preclinical evidence that PD-1 blockade boosts antiviral immunity, this study aims to evaluate the efficacy and safety of PD-1 inhibitors in chronic hepatitis B (CHB) patients who have failed interferon therapy. METHODS: This non-randomized controlled trial was conducted in CHB patients who failed to achieve HBsAg clearance after…

Rank45.0

Other PubMed-indexed publication

Virological and pathological characterization of an outbreak of domestic cat hepatitis B virus infection in a cat shelter in Japan.

The Journal of veterinary medical science · 2026 · PMID 41951368

Domestic cat hepatitis B virus (DCHBV) infections are associated with chronic hepatitis and hepatic cancer in cats, similar to human HBV. We previously demonstrated that the positivity rate for DCHBV in Japan is less than 1% among tested samples, suggesting lower viral dissemination in Japan than in other countries. Furthermore, the transmission dynamics of DCHBV remain poorly understood. In this study, we document the first recorded outbreak of DCHBV in a cat shelter in Japan, which had an unprecedentedly high pre…

Rank45.0

Other PubMed-indexed publication

Transcriptomic profiling of HBV transgenic mouse livers reveals ZBP1-associated necroptotic signaling.

Scientific reports · 2026 · PMID 42552328

Although transcriptome studies have been performed in cell culture models of HBV infection, the in vivo hepatic transcriptional response to persistent HBV expression remains incompletely characterized. In addition, whether HBV is associated with activation of necroptotic signaling in the liver has not been fully clarified. Therefore, this study aimed to: (1) define transcriptomic alterations in livers from an HBV transgenic mouse model; and (2) explore whether ZBP1-associated necroptotic signaling is present in HBV…

Rank45.0

Other PubMed-indexed publication

Molecular insights into domestic cat hepatitis B virus linking genome to function.

Veterinary research communications · 2026 · PMID 42068381

Domestic cat hepatitis B virus (DCHBV) is a member of the Hepadnaviridae family and has been associated with hepatocellular carcinoma (HCC) in cats. This study aimed to determine the prevalence of DCHBV and associations with feline immunodeficiency virus (FIV), feline leukaemia virus (FeLV) and feline coronavirus (FCoV) infections in cats in Serbia, and to characterise the detected DCHBV genomes. Whole blood, serum and liver samples from 308 animals were screened by real-time (RT-)PCR for DCHBV, FIV, FeLV, and FCoV…

Rank45.0

Other PubMed-indexed publicationResult signal: null

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic Plasmodium falciparum sporozoite challenge in mice.

Frontiers in immunology · 2026 · PMID 42220505

INTRODUCTION: The decline in protective antibody titers and efficacy over time of the circumsporozoite protein (CSP)-based RTS,S/AS01 and R21/Matrix-M vaccines highlights the need for improved vaccines. Sporozoite microneme protein essential for cell traversal-1 (SPECT-1) is a conserved Plasmodium falciparum (Pf) antigen that plays a key role in parasite movements while traversing host cells. Targeting SPECT-1 as an addition to the CSP in the same vaccine may enhance immune response and protection. METHODS: We engi…

Rank45.0

Other PubMed-indexed publication

Virus infections and cancers: from mechanisms to therapeutics.

Molecular biomedicine · 2026 · PMID 42417944

Viral infections are a major contributor to global cancer incidence and mortality. However, integrative reviews that connect viral classification, carcinogenic mechanisms, tumor microenvironment remodeling, and translational strategies remain limited. This review summarizes the classification and epidemiological characteristics of major oncogenic viruses, including human papillomavirus (HPV), Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), Merkel cell polyomavirus (MCPyV), human T-lympho…

Rank45.0

Other PubMed-indexed publication

Epidemiological and recombination analysis of duck hepatitis B virus in domestic ducks from Hunan province, China.

Comparative immunology, microbiology and infectious diseases · 2026 · PMID 42033854

Duck hepatitis B virus (DHBV), a member of the Avihepadnavirus genus, serves as an important model for human hepatitis B virus (HBV) due to shared genomic and replication features. Although typically asymptomatic in adult ducks, DHBV infection is associated with substantial economic losses in commercial flocks, including reduced egg hatchability and impaired duckling development. As the world's largest producer of waterfowl, China faces significant economic threats from such endemic viruses, highlighting the import…

Rank45.0

Other PubMed-indexed publication

Development of RPA and nested-RPA based CRISPR/Cas13a diagnostic platform for the identification of HBV DNA and HCV RNA in Indian patient cohort.

Diagnostic microbiology and infectious disease · 2026 · PMID 42289138

BACKGROUND: Among the Indian population, hepatitis B virus (HBV) is one of the major burdens and the hepatitis C virus (HCV) chronically infects around 1% Indian population. CRISPR-based detection platforms have shown to be a novel low-cost technology with high sensitivity and specificity. In the presence of target nucleic acids, Cas13a molecule is activated to trans-cleave the fluorophore quencher (FQ)-labeled ssRNA reporter, and illuminate detectable fluorescent signals. METHODS: Leptotrichia wadei (Lwa) cas13a w…

Rank45.0

Other PubMed-indexed publication

Double derivatization-enhanced LC-MS/MS for isomer-resolved identification and quantification of fatty acids.

Analytica chimica acta · 2026 · PMID 41644260

BACKGROUND: Fatty acids (FAs) are essential metabolites involved in energy storage, signaling, and inflammation regulation, and their biological functions are closely linked to the position and geometric configuration of carbon-carbon double bonds (CC). However, the isomer-resolved characterization and highly sensitive detection of FAs in complex biological matrices remain challenging due to their co-elution, similar fragmentation, and low ionization efficiency. Therefore, there remains a critical need for an effic…

Rank45.0

Other PubMed-indexed publication

Self-assembly of the domestic cat hepadnavirus core antigen (DCHcAg) into virus-like particles (VLPs).

Virology · 2026 · PMID 41833205

Domestic cat hepadnavirus (DCHBV) is an emerging Orthohepadnavirus associated with chronic hepatitis and hepatocellular carcinoma in cats, sharing structural similarity with human hepatitis B virus (HBV). We successfully expressed the DCHBV core antigen (DCHBVcAg) in a baculovirus-insect cell system and demonstrated its self-assembly into virus-like particles (VLPs). Full-length DCHBVcWT and C-terminally truncated DCHBVcN149 (residues 1-149) were expressed in Sf9 cells, formed dimers, and purified by sucrose gradie…

Rank45.0

Other PubMed-indexed publication

Coupling of Size Exclusion Chromatography to High Throughput Charge Detection Mass Spectrometry for the Analysis of Large Proteins and Virus-like Particles.

Analytical chemistry · 2025 · PMID 39878296

Charge detection mass spectrometry (CD-MS) is an emerging single-particle technique where both the m/z and charge are measured individually to determine each ion's mass. It is particularly well-suited for analyzing high mass and heterogeneous samples. With conventional MS, the loss of charge state resolution with high mass samples has hindered the direct coupling of MS to separation techniques like size exclusion chromatography (SEC) and forced the use of lower resolution detectors. Here, we show how CD-MS, leverag…

Rank45.0

Other PubMed-indexed publication

Wedelolactone Inhibits Hepatitis B Virus Replication by Modulating NF-κB and Nrf2/HO-1 Signaling: An in-vitro Huh7 1.3-mer HBV Plasmid Model.

Iranian journal of pharmaceutical research : IJPR · 2026 · PMID 42157795

BACKGROUND: Chronic hepatitis B virus (HBV) infection is a well-recognized cause of hepatic injury through prolonged viral replication, inflammation, and oxidative stress. Existing antiviral drugs limit viral replication but cannot eliminate viral transcription or even totally preclude liver injury, thus reemphasizing the significance of drugs with combined antiviral and hepatoprotective effects. OBJECTIVES: To evaluate the effects of wedelolactone on HBV replication, gene expression, inflammation, and oxidative st…

Rank45.0

Other PubMed-indexed publication

Assessment of the fish tumors or other deformities beneficial use impairment and associated risks at two Lake Michigan Areas of Concern.

Ecotoxicology (London, England) · 2026 · PMID 41483024

The U.S. Great Lakes Areas of Concern (AOCs) have been designated due to significant environmental degradation, with multiple Beneficial Use Impairments (BUIs) requiring remediation before delisting. The “fish tumors or other deformities” BUI remains at the Sheboygan River and the Lower Green Bay and Fox River AOCs, necessitating evaluation in white sucker (Catostomus commersonii), a sentinel species. This study documented the prevalence of skin and liver neoplastic and preneoplastic lesions at these AOCs, assessed…

Rank42.0

Other PubMed-indexed publication

NK cells limit therapeutic vaccine-induced CD8+T cell immunity in a PD-L1-dependent manner.

Science translational medicine · 2022 · PMID 35417187

A better understanding of mechanisms that regulate CD8+T cell responses to therapeutic vaccines is needed to develop approaches to enhance vaccine efficacy for chronic viral infections and cancers. We show here that NK cell depletion enhanced antigen-specific T cell responses to chimp adenoviral vector (ChAdOx) vaccination in a mouse model of chronic HBV infection (CHB). Probing the mechanism underlying this negative regulation, we observed that CHB drove parallel up-regulation of programmed cell death ligand 1 (PD…

Rank37.0

Case report

Meropenem treatment failure in severe melioidosis despite in vitro susceptibility: A case report.

IDCases · 2026 · PMID 42382259

Burkholderia pseudomallei causes melioidosis, a potentially life-threatening infection that can rapidly progress to septic shock and multi-organ failure if not promptly recognized and treated. Current international guidelines recommend meropenem as first-line therapy for severe melioidosis, whereas prolonged oral eradication therapy is essential to prevent relapse. We report a 39-year-old man with diabetes mellitus and chronic hepatitis B who initially improved on intravenous ceftazidime for disseminated melioidosi…

Rank36.1

Preclinical or laboratory study

Neu5Gc-associated Serum Immunoglobulin G Glycosylation as a Diagnostic Biomarker for Hepatocellular Carcinoma.

Journal of clinical and translational hepatology · 2026 · PMID 42181844

BACKGROUND AND AIMS: Given the lack of efficient biomarkers for hepatocellular carcinoma (HCC) diagnosis, this study aimed to develop an HCC diagnostic strategy based on serum protein glycosylation signatures. We characterized differential N-glycosylation patterns of serum IgG to differentiate HCC from healthy controls and liver cirrhosis, and elucidated the molecular mechanisms driving aberrant Neu5Gc elevation in HCC to provide a theoretical basis for clinical application and differential diagnosis of HCC. METHOD…

Rank35.6

Preclinical or laboratory study

Hyperhomocysteinemia reduces the high-quality embryo rate in PCOS patients undergoing IVF/ICSI: clinical evidence and a preliminary exploration of mechanisms in KGN cells.

Journal of ovarian research · 2026 · PMID 42129831

BACKGROUND: Homocysteine (Hcy) is a sulfur-containing intermediate metabolite during methionine metabolism. Studies indicate that individuals with polycystic ovary syndrome (PCOS) have higher circulating Hcy levels relative to unaffected populations. Hyperhomocysteinemia (HHcy) has been implicated in multisystem cytotoxicity. This study was designed to evaluate the association between Hcy levels and embryo quality and pregnancy outcomes in PCOS patients undergoing assisted reproductive technologies (ART). Mechanist…

Rank35.0

Case report

Distribution of domestic cat hepatitis B virus in cholangiocarcinoma and non-neoplastic liver tissue.

The Journal of veterinary medical science · 2026 · PMID 41526269

Domestic cat hepatitis B virus (DCHBV), shares similarities with human hepatitis B virus (HBV) which is associated with liver disease. We report the first case of cholangiocarcinoma in a 17-year-old spayed female cat infected with DCHBV and positive for feline immunodeficiency virus. The patient presented with vomiting, anorexia, and an elevated globulin level. Ultrasonography revealed multiple hypoechoic hepatic lesions, and histopathology confirmed cholangiocarcinoma. The tumor exhibited CK7 positivity and HepPar…

Rank34.1

Preclinical or laboratory studyResult signal: null

Impact of hepatitis B virus carrier status on IVF-ET outcomes across different ovarian reserve levels: A retrospective study.

Medicine · 2026 · PMID 42152314

To evaluate the impact of hepatitis B virus (HBV) carrier status on oocyte quality, embryonic development, and pregnancy outcomes in women with varying ovarian reserve undergoing in vitro fertilization and embryo transfer (IVF-ET). This retrospective study included 112 infertile women with HBV carrier status and 104 HBV-negative controls who underwent IVF-ET between December 2020 and December 2024. Participants were stratified by serum anti-müllerian hormone levels into low (<2 μg/L), normal (2-7 μg/L), and high (>…

Rank34.1

Preclinical or laboratory study

RRM2B is associated with low-level viremia during entecavir therapy in pediatric chronic hepatitis B and promotes profibrotic signaling in vitro.

Virology journal · 2026 · PMID 42436559

BACKGROUND: Low-level viremia (LLV) during nucleos(t)ide analogue therapy for chronic hepatitis B (CHB) is clinically relevant, but its biological basis in children remains unclear. We investigated the clinical features of pediatric LLV and sought host factors linking incomplete virological suppression to stress adaptation and profibrotic signaling. METHODS: Children with CHB who initiated entecavir therapy between 2019 and 2024 were retrospectively enrolled. LLV and maintained virological response (MVR) were defin…

Rank33.9

Preclinical or laboratory study

Plasma gamma-glutamylglycine predicts the seroconversion of hepatitis B e antigen in patients with chronic hepatitis B.

Frontiers in immunology · 2026 · PMID 42338590

BACKGROUND: The seroconversion of hepatitis B e antigen (HBeAg) remains difficult to be completely obtained in the treatment of hepatitis B. This study aimed to characterize the metabolic signatures of HBeAg-positive patients and identify key metabolites associated with HBeAg seroconversion. METHODS: Untargeted metabolomic analysis was conducted to investigate the plasma metabolic profiles of HBeAg-positive (n=54) and negative (n=33) patients. Subgroup analyses were performed in patients with persistent HBeAg<20IU/…

Rank33.0

Preclinical or laboratory study

Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy.

Hepatology communications · 2026 · PMID 42190271

BACKGROUND: Although nucleos(t)ide analogs (NAs) suppress HBV replication, functional cure-defined by hepatitis B surface antigen (HBsAg) loss-is rarely achieved in chronic hepatitis B (CHB). Immune correlates of HBsAg decline may inform new therapeutic strategies. METHODS: We profiled peripheral blood mononuclear cells (PBMCs) from NA-treated CHB patients with declining versus sustained HBsAg levels by single-cell RNA sequencing (scRNA-seq), followed by validation in an independent multicenter cohort using transcr…

Promising Experimental Therapies72 records

Rank106.9

Systematic review or meta-analysis

Entecavir for children and adults with chronic hepatitis B.

The Cochrane database of systematic reviews · 2025 · PMID 40260837

Rank100.0

Systematic review or meta-analysis

Interventions to Increase Hepatitis B Testing Uptake Amongst Detained Populations: A Systematic Review.

Journal of viral hepatitis · 2026 · PMID 42163587

People who have been detained have a higher prevalence of hepatitis B virus (HBV) than the general population, yet testing uptake remains limited. Improving testing uptake in high-risk settings is essential to the World Health Organization 2030 elimination target. This systematic review examines interventions aimed at increasing hepatitis B testing uptake in prison. MEDLINE, EMBASE, CENTRAL and CINAHL were searched from January 2000 to April 2025. Quantitative interventional studies were included. Quality appraisal…

Rank99.8

Randomized controlled trial

Huangjia Ruangan granules with entecavir for fibrosis regression in Chroinc Hepatitis B: A multicenter, randomized, double-blind, phase II trial.

Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025 · PMID 41138575

BACKGROUND: Huangjia Ruangan Granules (HRG) has shown promising therapeutic effects in treating hepatic fibrosis in China. This study aimed to assess its specific efficacy. METHODS: This 48-week phase II study was a multicenter, randomized, double-blind, placebo-controlled trial conducted at 14 centers in China (No. ChiCTR2400086796). patients with chronic hepatitis B (CHB) and an Ishak fibrosis score between 2 to 5 were eligible for inclusion. Patients were randomly assigned to three groups (1:1:1 ratio): ETV (0.5…

Rank99.0

Randomized controlled trialResult signal: benefit

Hepatology communications · 2026 · PMID 42486799

BACKGROUND: Chronic HBV and HDV coinfection represents the most severe form of viral hepatitis. This study aimed to assess the safety and efficacy of libevitug (HH-003), a novel human monoclonal antibody targeting the PreS1 domain of the HBV large envelope protein, in patients with chronic HBV and HDV coinfection. METHODS: This single-center, open-label, proof-of-concept phase IIa clinical trial enrolled 9 participants who received i.v. infusion of 20 mg/kg libevitug every 2 weeks for 24 weeks, followed by a 24-wee…

Rank77.0

Phase II clinical trial

Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients.

CPT: pharmacometrics & systems pharmacology · 2025 · PMID 40838600

Pegbing (peginterferon alpha-2b) is a polyethylene glycol-modified interferon α-2b injection that has demonstrated favorable efficacy and safety profiles in the treatment of chronic hepatitis B (CHB). This study aimed to develop a population pharmacokinetic (PopPK) model of Pegbing in both healthy subjects and CHB patients and to investigate the influence of covariates on its pharmacokinetic behavior. Pharmacokinetic data were obtained from a Phase I trial in healthy volunteers and a Phase II trial in CHB patients.…

Prospective Cohort Studies60 records

Rank101.0

Randomized controlled trial

External Validation of the GOLDEN Model for Predicting HBsAg Loss in Noncirrhotic Chronic Hepatitis B Patients With Interferon-Alpha-Based Therapy.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · PMID 40562289

BACKGROUND & AIMS: GOLDEN model is designed to predict hepatitis B surface antigen (HBsAg) loss based on patients with chronic hepatitis B (CHB) receiving nucleos(t)ide analogues therapy. We aimed to validate GOLDEN model's effectiveness in predicting HBsAg loss or decline in interferon-α-treated patients with CHB. METHODS: Interferon-α-treated patients were enrolled from EXCEL study, a randomized controlled trial that included hepatitis B e antigen-positive, noncirrhotic, treatment-naive patients with CHB, and Sea…

Rank96.2

Randomized controlled trial

Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B.

JHEP reports : innovation in hepatology · 2026 · PMID 42067192

BACKGROUND & AIMS: Hepatic flares frequently occur after nucleos(t)ide analogue (NA) cessation in patients with chronic hepatitis B (CHB) and can be beneficial ('good flares') or harmful ('bad flares'). We characterised flares after NA cessation aiming to identify predictors and immunological correlates of good and bad flares. METHODS: This study was nested in the prospective Nuc-Stop study, in which 127 patients with e-antigen negative CHB discontinued NA treatment with a 36-month follow-up. Flares were defined as…

Rank95.6

Randomized controlled trialResult signal: null

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial.

Journal of viral hepatitis · 2026 · PMID 41608776

The optimal strategy for chronic hepatitis B virus (HBV) infected patients with negative hepatitis B e-antigen (HBeAg) and normal alanine aminotransferase (ALT) remains uncertain. This study aimed to evaluate the safety and efficacy of tenofovir alafenamide fumarate (TAF) treatment in this patient population. This prospective, open-label, randomised controlled trial enrolled HBeAg-negative patients with normal ALT and randomised them 1:1 to either the treatment group (TAF) or the control group (no treatment). The p…

Rank94.2

Randomized controlled trialCorrection flagged

Comparison of the impact of shunting the left versus right portal vein branch during TIPS on the postoperative overt hepatic encephalopathy: a randomized trial.

Hepatology international · 2026 · PMID 40965723

BACKGROUND AND AIM: The effect of shunting the left or right branch of the portal vein on the post-transjugular intrahepatic portosystemic shunt (TIPS) hepatic encephalopathy (HE) remains controversial. Therefore, we designed this prospective, randomized, single-blinded trial to compare the incidence of HE after shunting the left or right branch of the portal vein during TIPS in cirrhotic patients to prevent variceal rebleeding. METHODS: Consecutive patients diagnosed with hepatitis B virus (HBV)-related cirrhosis …

Rank92.0

Randomized controlled trial

Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controlled Trial (SPHERE) Protocol.

Advances in therapy · 2026 · PMID 42176181

Rank80.6

Phase II clinical trial

The Journal of infection · 2026 · PMID 41763570

OBJECTIVE: Our prior interim report remains the only prospective study evaluating tenofovir alafenamide (TAF) for HBV reactivation prevention, with prophylaxis assessed up to 12 months. Herein, we report the final 24-month follow-up results. METHODS: This multicentre prospective-study enrolled HBV carriers who received prophylactic TAF before antineoplastic or immunosuppressive therapy and patients with resolved HBV infection who developed reactivation and received TAF as reactivation-related hepatitis prophylaxis.…

Rank69.6

Prospective cohort study

Breastfeeding practices among hepatitis b-infected mothers: a prospective cohort study.

BMC pregnancy and childbirth · 2026 · PMID 41749120

BACKGROUND: Mother-to-child transmission (MTCT) remains a primary route of Hepatitis B virus (HBV) infection in China. Despite World Health Organisation (WHO) recommendations supporting the safety of breastfeeding under timely immunoprophylaxis, rates among HBV-infected mothers in China remain low. OBJECTIVE: To investigate breastfeeding practices, maternal perceptions, and factors influencing feeding decisions among HBV-infected mothers whose infants received standard immunoprophylaxis. METHODS: Between April 2016…

Quality Of Life62 records

Rank110.8

Systematic review or meta-analysis

Vaccines for preventing infections in adults with haematological malignancies.

The Cochrane database of systematic reviews · 2025 · PMID 40396505

Rank109.8

Systematic review or meta-analysis

Vaccines for preventing infections in adults with solid tumours.

The Cochrane database of systematic reviews · 2025 · PMID 40237463

BACKGROUND: Infections are one of the most frequent complications seen in adults with cancer, often arising from the underlying condition or as a result of immunosuppressive treatments. Certain infections (e.g. influenza, pneumococcal disease, and meningococcal disease) may be prevented through vaccination. However, adults with solid tumours may elicit varying immune responses compared to healthy individuals. OBJECTIVES: To assess the benefits and risks of vaccines for the prevention of infectious diseases in adult…

Rank106.9

Systematic review or meta-analysis

Entecavir for children and adults with chronic hepatitis B.

The Cochrane database of systematic reviews · 2025 · PMID 40260837

Rank100.0

Systematic review or meta-analysis

Global Systematic Review of the Measurement of Stigma Associated With People Living With Hepatitis B or Hepatitis C Viruses.

Journal of viral hepatitis · 2025 · PMID 40856266

Chronic hepatitis B and C affect over 300 million people globally. Despite treatment advances, stigma towards people living with hepatitis B/C (PLWHB/C) remains a barrier to care and impacts health outcomes. Addressing this stigma is key to achieving hepatitis elimination goals. This systematic review aims to synthesise existing approaches to measuring stigma experienced by PLWHB/C and examine factors associated with stigma in different social contexts. Databases searched included PubMed, PsycInfo and Web of Scienc…

Rank100.0

Systematic review or meta-analysis

Utility of mobile applications in the management of hepatitis B: A systematic review.

Gastroenterologia y hepatologia · 2025 · PMID 39983899

Hepatitis B virus is a public health issue, with severe complications such as cirrhosis and liver cancer that impose significant economic, emotional, and psychosocial burdens. Despite the availability of a vaccine and oral treatments, effective management of this disease remains a challenge. Telemedicine and mobile applications have the potential to improve the management of chronic diseases; this study examines their utility in hepatitis B. A search was conducted in four databases in November 2024 following the PR…

Rank96.2

Randomized controlled trial

Efficacy and Safety of Erzhu Jiedu Decoction Granules in Treating Mid-advanced Hepatitis B Virus-Associated Primary Liver Cancer Patients with Pi (Spleen)-Deficiency and Dampness-Heat Syndrome.

Chinese journal of integrative medicine · 2025 · PMID 39636494

OBJECTIVE: To assess the efficacy and safety of Erzhu Jiedu Decoction (EZJDD) Granules in treating mid-advanced hepatitis B virus-associated primary liver cancer (HBV-PLC) patients with Pi (Spleen)-deficiency and dampness-heat syndrome. METHODS: From January 2021 to June 2023, a cohort of 132 patients were enrolled and randomly assigned to a control group or a EZJDD group according to the random numbers, with 66 patients in each group. The patients in the control group received conventional treatment for 3 months, …

Rank96.0

Systematic review or meta-analysis

Integrated care management model for liver transplantation: a narrative review and single-center implementation experience.

Translational gastroenterology and hepatology · 2026 · PMID 41675341

BACKGROUND AND OBJECTIVE: Liver transplantation (LT) is the most effective end-stage liver disease (ESLD) therapeutic intervention. However, in China, many liver transplant recipients lack a comprehensive management approach. This narrative review summarizes the current deficiencies in long-term post-transplant care and proposes a comprehensive model for Integrated Care Management (ICM) aimed at improving long-term outcomes after LT. METHODS: An extensive electronic literature search was performed using PubMed data…

Rank89.7

Randomized clinical study

Efficacy and safety of Yangxiao Fukang granule in the treatment of stage Ⅲ hepatitis B related liver cancer: study protocol for a randomized controlled trial.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025 · PMID 41015811

Primary liver cancer (PLC) is the third major cause of cancer related death, which seriously affects the survival period and quality of life of patients. However, there is currently no evidence to prove which treatment method is most effective. Traditional Chinese Medicine (TCM) has shown certain advantages in the treatment of PLC, especially in the side effects of Western Medicine. Therefore, we designed a clinical trial protocol for the treatment of PLC using TCM granules. Our purpose is to explore the efficacy a…

Rank88.2

Randomized clinical study

Effect of an Integrated Exercise Training Program on Muscle Mass and Functional Capacity in Sarcopenic Patients With Decompensated Liver Cirrhosis.

Cureus · 2026 · PMID 42577566

Rank76.9

Multicenter clinical study

Impact of Fatigue on Patient-Reported Outcomes and Work Productivity in Chronic Hepatitis B and C: Insights From a Multinational Registry Study.

Journal of viral hepatitis · 2026 · PMID 42144799

Fatigue in chronic viral hepatitis may be associated with decreased health-related quality of life and other patient-reported outcomes (PROs). We evaluated the relationship between fatigue and PROs in patients with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Patients with CHB and CHC enrolled in the Global Liver Registry completed PRO instruments: FACIT-F, CLDQ (for CHB), CLDQ-HCV (for CHC), and WPAI:SHP. Fatigue was defined as FACIT-F Fatigue Scale (FS) score < 30 (scale range: 0-52). Among 2888 patie…

Rank76.8

Multicenter clinical study

Meaningful differences in patient-reported outcome measurement scores in liver disease.

Hepatology communications · 2025 · PMID 40434652

BACKGROUND: Patient-reported outcome measures (PROMs) are being used more often in chronic liver disease (CLD) clinical care and research. Their interpretability can be greatly enhanced by establishing the smallest meaningful score difference (MSD). We report scores of commonly used PROMs and their MSDs in patients at different stages of liver disease. METHODS: Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Profile, Chronic Liver Disease Questionnaire (CLDQ), and Short Form-36 (SF-36) v1.0 sco…

Rank65.0

Prospective cohort study

[Chronic HBV infection affects health-related quality of life in pregnant women in the second and third trimesters and postpartum period: a prospective cohort study].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025 · PMID 40415431

OBJECTIVES: To evaluate the impact of HBV infection on pre- and postpartum health-related quality of life (HRQoL) in pregnant women. METHODS: A prospective matched cohort consisting of 70 HBV-infected and 70 healthy pregnant women was recruited from the Fifth Affiliated Hospital of Guangzhou Medical University between April 17 and September 25, 2023. HRQoL of the participants was assessed at 16-24 weeks of gestation, between 32 weeks and delivery, and 5-13 weeks postpartum. Mixed linear models were used for evaluat…

Rank53.3

Other PubMed-indexed publication

Development and Validation of a Prediction Model for Overt Hepatic Encephalopathy (OHE) After Transjugular Intrahepatic Portosystemic Shunt: A Multicenter Retrospective Study.

Journal of clinical and experimental hepatology · 2026 · PMID 41815830

BACKGROUND: Hepatic encephalopathy (HE), especially overt HE (OHE), is the most common transjugular intrahepatic portosystemic shunt (TIPS) complication, affecting quality of life. Existing noninvasive models have suboptimal predictive performance. AIM: To develop a novel model integrating preoperative and intraoperative indicators to predict post-TIPS OHE. METHODS: We included 455 TIPS patients from three centers (Army Medical Center, Xinqiao Hospital, and West China Hospital) between March 2018 and September 2024…

Rank52.3

Other PubMed-indexed publication

Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes.

Journal of gastroenterology and hepatology · 2026 · PMID 42419754

BACKGROUND: Hepatitis B virus (HBV), hepatitis C virus (HCV), and metabolic dysfunction-associated steatotic liver disease (MASLD) are common liver diseases. Clinical characteristics and patient-reported outcomes (PROs) of HBV and HCV patients with/without superimposed MASLD were evaluated. METHODS: Cross-sectional study of clinical and PRO (FACIT-Fatigue [FACIT-F], Chronic Liver Disease Questionnaire [CLDQ], Work Productivity and Activity Impairment [WPAI] questionnaire) data from Global Liver Registry, HBV and HC…

Rank51.2

Other PubMed-indexed publication

Chronic liver disease questionnaire analysis in pregnant women with hepatitis B: a prospective study.

BMC pregnancy and childbirth · 2026 · PMID 42151851

BACKGROUND: Although domestic and international guidelines increasingly emphasize preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV), the multidimensional impacts of HBV infection on pregnant women's health-related quality of life (HRQoL) have received insufficient attention. Our previous 1:1 matched cohort study [1] identified HBV infection as an independent risk factor for impaired HRQoL in pregnant women, after adjusting for age, gestational age, and parity. Building upon this foundation, …

Rank50.4

Other PubMed-indexed publication

Quantitatively Evaluate the Improvement of Functional Cure for the Quality of Life of Chronic Hepatitis B Cases: Evidence from a Cross-Sectional Study in China.

Healthcare (Basel, Switzerland) · 2025 · PMID 41154268

Background: Functional cure of chronic hepatitis B (CHB) can be achieved with appropriate antiviral treatment. However, few studies have evaluated the added benefits of achieving functional cure. We aimed to conduct a quantitative analysis of the health-related quality of life (HRQoL) of CHB patients who achieved functional cure to provide evidence for economic analysis. Methods: We conducted a cross-sectional study in five provinces in China in 2021. The study population was recruited in hospitals and divided into…

Rank50.3

Other PubMed-indexed publication

Comorbidity Burden and Biologic Access in an Uninsured Psoriasis Population: A 20-Year Descriptive Study.

International journal of dermatology · 2026 · PMID 41609515

BACKGROUND: Psoriasis is a chronic immune-mediated disease associated with multiple systemic comorbidities. Biologic therapies have transformed the management of moderate-to-severe psoriasis; however, their high cost remains a major barrier for uninsured and socioeconomically disadvantaged individuals. The Psoriasis Biologics Center for Indigent Patients at Jackson Memorial Hospital provides a structured dermatology access model for underserved populations. METHODS: We conducted a descriptive retrospective cohort s…

Rank50.2

Other PubMed-indexed publication

Enhancing Chronic Hepatitis B and D Management Through a Tailored Mobile Health Application: Real-World Outcomes From the Adaptation of the NORA App.

Journal of viral hepatitis · 2026 · PMID 41731678

Chronic hepatitis B (CHB) and hepatitis D (CHD) remain global health challenges, where sustained care engagement, treatment adherence and regular monitoring are essential but often limited by stigma and healthcare access. Digital health tools offer new opportunities to bridge these gaps. This study aimed to adapt the NORA mobile health app for CHB and CHD patients and evaluate its real-world utility in improving knowledge, adherence, communication and quality of life. We conducted a prospective, comparative study (…

Rank50.0

Other PubMed-indexed publication

Health-related Quality of Life in Patients With Chronic Hepatitis B and Liver-Related Complications in The Gambia.

Value in health regional issues · 2026 · PMID 42240545

OBJECTIVES: Health related quality of life (HRQoL) in chronic hepatitis B infection (CHB) is poorly studied in Africa despite the high burden of disease. We aimed to assess HRQoL and health utility (HU) across different stages of infection and liver-related disease in The Gambia, West Africa. METHODS: A cross-sectional study was carried out between January and November 2019. Participants were recruited from outpatient clinics and inpatient wards. Patients were stratified into 5 disease stages CHB not meeting treatm…

Rank49.7

Other PubMed-indexed publication

MRI-based machine-learning radiomics of the liver to predict liver-related events in hepatitis B virus-associated fibrosis.

European radiology experimental · 2025 · PMID 40864355

BACKGROUND: The onset of liver-related events (LREs) in fibrosis indicates a poor prognosis and worsens patients' quality of life, making the prediction and early detection of LREs crucial. The aim of this study was to develop a radiomics model using liver magnetic resonance imaging (MRI) to predict LRE risk in patients undergoing antiviral treatment for chronic fibrosis caused by hepatitis B virus (HBV). METHODS: Patients with HBV-associated liver fibrosis and liver stiffness measurements ≥ 10 kPa were included. F…

Rank49.6

Other PubMed-indexed publication

Eligibility for Intramuscular Cabotegravir/Rilpivirine in HIV-Positive Patients: An Observational Study.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2025 · PMID 40352251

Background: HIV treatment has advanced significantly with the introduction of simpler antiretroviral regimens, but adherence remains a challenge. In this context, the long-acting injectable combination cabotegravir/rilpivirine (CAB/RPV) emerges as a promising alternative to improve adherence and quality of life for patients. Objective: The purpose of this study was to determine the proportion of patients with HIV-1 on antiretroviral therapy (ART) who meet the criteria for the use of intramuscular CAB/RPV. Methods: …

Rank49.6

Other PubMed-indexed publication

Psychiatric symptoms and necroinflammatory activity in chronic hepatitis B: a cross-sectional study.

BMC infectious diseases · 2025 · PMID 41239311

BACKGROUND: Patients with chronic hepatitis B (CHB) are at risk of developing psychiatric symptoms such as depression, anxiety, and fatigue, which may adversely affect quality of life, treatment adherence, and disease outcomes. Emerging evidence suggests that these psychological symptoms are influenced not only by psychosocial stressors but also by biological mechanisms related to hepatic necroinflammation and fibrosis. This study aimed to investigate the relationship between depression, anxiety, fatigue, and non-i…

Rank49.5

Other PubMed-indexed publication

Primary versus systemic sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors.

Clinical and experimental rheumatology · 2025 · PMID 40183325

OBJECTIVES: Raynaud's phenomenon (RP) can be induced by stress and environmental factors, occurring as a primary disease (pRP) or associated with connective tissue disease. RP is seen in more than 95% of patients with systemic sclerosis (SSc) and may precede its diagnosis by several years. Accordingly, there is a clear need to identify those patients with RP who will eventually develop connective tissue disease, including SSc. The aim of this case-control study was to assess the association of SSc-RP versus pRP wit…

Rank48.5

Other PubMed-indexed publication

Evaluation of Quality of Life and Risk Factors in Patients With Covert Hepatic Encephalopathy Including Those With Hepatocellular Carcinoma.

Cancer diagnosis & prognosis · 2026 · PMID 42078318

BACKGROUND/AIM: Covert hepatic encephalopathy (CHE) is associated with a decline in quality of life (QOL), requiring early detection and intervention. We aimed to determine CHE prevalence, QOL correlations, and risk factors in hospitalized patients with cirrhosis. This study evaluated neuropsychological test (NPT) results and QOL in these patients. PATIENTS AND METHODS: This retrospective study included 56 patients with liver cirrhosis who were hospitalized at our institution from January to November 2024 and under…

Rank48.4

Other PubMed-indexed publication

Comparison of the long-term effects of digestive endoscopy variceal ligation and propranolol in preventing variceal rebleeding in patients with liver cirrhosis.

Medicine · 2026 · PMID 41731834

This study aimed to assess the long-term effects of endoscopic variceal ligation (EVL) and propranolol in preventing variceal rebleeding in patients with liver cirrhosis and esophageal varices. A retrospective analysis was conducted on patients with hepatitis B-related liver cirrhosis and class A Child-Pugh scores who received either EVL (n = 51) or propranolol (n = 53) for variceal rebleeding prevention. Baseline characteristics, hemodynamic parameters, variceal rebleeding frequency, complications, quality-of-life…

Randomized Controlled Trials60 records

Rank108.5

Systematic review or meta-analysis

The incidence of spontaneous HBsAg loss in patients with different baseline HBsAg levels: a systematic review and meta-analysis.

Hepatology international · 2026 · PMID 41686332

Rank108.3

Systematic review or meta-analysis

Efficacy and safety of clipping prior to cyanoacrylate embolization in gastric varices: a single-arm systematic review and meta-analysis.

Surgical endoscopy · 2026 · PMID 42377512

Rank107.7

Systematic review or meta-analysisResult signal: benefit

First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety.

Frontiers in immunology · 2026 · PMID 42220514

Rank107.5

Systematic review or meta-analysis

Effectiveness of Digital Health Interventions to Improve Self-Care in Patients With Chronic Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of medical Internet research · 2026 · PMID 42263266

Rank106.7

Systematic review or meta-analysisResult signal: benefit

Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis.

BMC infectious diseases · 2026 · PMID 42288778

Rank106.3

Systematic review or meta-analysis

Gut and liver · 2026 · PMID 42015653

Rank99.2

Randomized controlled trial

Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial.

Hepatology international · 2026 · PMID 42213313

OBJECTIVES: The objective of this study was to investigate the efficacy and safety of oral tolvaptan for hyponatremia in patients with cirrhosis in China. PATIENTS AND METHODS: In this post hoc subgroup analysis of a phase 2 clinical trial of oral tolvaptan for hyponatremia due to cirrhosis, heart failure, and syndrome of inappropriate antidiuretic hormone secretion in China, patients with hyponatremia due to cirrhosis received placebo or tolvaptan for 7 days (15 mg titrated to 30 or 60 mg/day). The primary endpoin…

Rank99.0

Randomized controlled trialResult signal: benefit

[Clinical study on the efficacy of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia patients with chronic hepatitis B].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026 · PMID 42373438

Rank98.9

Randomized controlled trial

The New England journal of medicine · 2026 · PMID 42206582

Rank97.4

Randomized controlled trial

Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · PMID 40953786

Rank97.3

Randomized controlled trial

Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial.

The lancet. HIV · 2026 · PMID 42140217

BACKGROUND: Previous trials have validated the strategy of short-cycle three-drug (triple) antiretroviral therapy for HIV treatment. The main objective of ANRS-177 DUETTO was to assess whether a two-drug (dual) regimen taken on 4 consecutive days per week (4/7-days) was virologically non-inferior to standard dual therapy regimen taken 7 days per week (7/7-days) in participants with HIV and sustained viral suppression. METHODS: This open-label, randomised, parallel, multicentre, non-inferiority trial enrolled adults…

Rank96.5

Randomized controlled trial

The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial.

The lancet. Gastroenterology & hepatology · 2026 · PMID 42173110

Rank96.4

Randomized controlled trial

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial.

Journal of hepatology · 2026 · PMID 41966308

BACKGROUND & AIMS: Bulevirtide is approved in several countries and regions for the treatment of compensated chronic hepatitis D (CHD). However, long-term outcomes after treatment discontinuation remain unknown. METHODS: Patients with CHD (n = 150) were randomized to immediate treatment with bulevirtide 2 mg/day (n = 49) or 10 mg/day (n = 50) for 144 weeks (W), or a 48W delay before starting treatment (DT; n = 51) followed by bulevirtide 10 mg/day for 96W (DT/10 mg; n = 50), and 96W of post-treatment follow-up (FU9…

Safety And Adverse Effects60 records

Rank110.0

Clinical guideline or consensus statement

Vaccination and Safe Living Strategies for Solid Organ Transplant Candidates and Recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026 · PMID 42632426

These updated guidelines of the AST IDCOP review safe living practices including routine vaccinations, travel vaccinations including general travel advice, as well as non-pharmacological strategies for safe living. General principles of vaccination as well as the use of specific vaccines in this population are discussed. Vaccination status should be reviewed and updated in the pre-transplant setting and when travel is planned. The optimal timing of vaccination post-transplant should be taken into account. There are…

Rank100.0

Systematic review or meta-analysisResult signal: benefit

Efficacy of NAs in combination with Peg-IFN for functional cure in patients with CHB: a meta-analysis of RCTs.

Annals of medicine · 2026 · PMID 41777119

Rank98.0

Randomized controlled trial

Annals of surgical oncology · 2026 · PMID 42045725

BACKGROUND: Post-hepatectomy liver failure (PHLF) is a serious complication after liver resection for hepatocellular carcinoma (HCC). However, reliable predictive models for PHLF in patients undergoing major hepatectomy remain limited. This study aimed to predict PHLF using clinical factors and to evaluate its impact on short- and long-term outcomes for patients with HCC undergoing major liver resection. METHODS: This multicenter retrospective study included 1037 patients undergoing liver resection exceeding sectio…

Rank77.0

Phase II clinical trial

Safety and efficacy of libevitug in patients with chronic hepatitis B and D virus coinfection: A single-center, open-label, phase IIa trial in China.

Hepatology communications · 2026 · PMID 42486799

Rank76.3

Multicenter clinical study

Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study.

Oncology research · 2026 · PMID 42630704

Introduction: Durvalumab plus tremelimumab (Durva/Treme) improved survival in the HIMALAYA trial for unresectable hepatocellular carcinoma (HCC), but real-world evidence remains limited. This study aimed to evaluate clinical outcomes of Durva/Treme in routine practice. Methods: This retrospective multicenter study included patients with unresectable or advanced HCC who received Durva/Treme through the Expanded Access Program in Thailand between August 2023 and November 2025. Treatment outcomes and adverse events (A…

Rank74.1

Multicenter clinical studyResult signal: null

Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.

British journal of haematology · 2026 · PMID 42226728

Although antiviral prophylaxis is standard for lymphoma patients with chronic hepatitis B virus (HBV) infection to prevent HBV reactivation (HBVr), the optimal timing for high-risk patients (baseline HBV deoxyribonucleic acid (DNA) ≥4 log10 IU/mL) during immunochemotherapy remains unclear. A multicentre retrospective study analysed 112 chronic HBV patients among 1120 newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, stratified by baseline viral load (low: <104 IU/mL, n = 82; high: ≥104 IU/mL, n = 30).…

Rank73.0

Multicenter clinical study

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.

Human vaccines & immunotherapeutics · 2026 · PMID 42359964

Preterm infants are at higher risk of mortality, disabilities, and infections. Hexavalent DTaP-IPV-HB-Hib vaccines against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b are standards of care in pediatric immunization. Evidence on the use of these vaccines in preterm infants remains limited, particularly in extreme preterms. This open-label, multicenter, non-randomized phase IV trial conducted in Spain evaluated the immunogenicity and safety of a 2 + 1 schedule of the …

Rank66.1

Observational or cohort study

Evaluating the risk: Hepatitis B virus reactivation in ocrelizumab-treated patients with multiple sclerosis: A single-center experience and review of the literature.

Multiple sclerosis and related disorders · 2026 · PMID 42431141

Rank65.8

Observational or cohort study

Viral infectious characteristics of cornea donors from the Londrina eye bank: a retrospective study and the impact of the COVID-19 pandemic.

Arquivos brasileiros de oftalmologia · 2026 · PMID 42561317

PURPOSE: To evaluate the impact of the COVID-19 pandemic and characterize the serological profile of discarded corneal donations in the coverage area of the Banco de Olhos de Londrina, through reverse transcription-polymerase chain reaction testing for COVID-19 and serological screening of cornea donors excluded because of positive test results. METHODS: This observational retrospective study included 776 cornea donors who's serological and reverse transcription-polymerase chain reaction test results were processed…

Rank64.8

Observational or cohort study

Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study.

Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42531850

OBJECTIVE: This study evaluated the efficacy and hepatic safety of first-line chemoimmunotherapy in lung cancer patients according to baseline hepatitis B surface antigen (HBsAg) status, and explored whether baseline anti-HBs level was associated with outcomes among HBsAg-negative/anti-HBc-positive patients. METHODS: We conducted a single-center retrospective observational cohort study of consecutive lung cancer patients who received first-line chemoimmunotherapy between June 1, 2019 and July 31, 2024. Patients wer…

Rank53.6

Other PubMed-indexed publication

Prevalence of renal and bone risk factors and nucleos(t)ide analogue treatment among patients with chronic hepatitis B in the United States.

Journal of managed care & specialty pharmacy · 2026 · PMID 42424106

BACKGROUND: Chronic hepatitis B (CHB) can lead to serious health complications. Patients with CHB often have a higher burden of extrahepatic comorbidities such as chronic kidney disease (CKD) and osteopenia/osteoporosis (OP) compared with the general population. Understanding the burden of these comorbidities in those with CHB may facilitate the development of strategies to better support patients and guide treatment decisions. OBJECTIVE: To evaluate demographic characteristics and prevalence of CKD, OP, and establ…

Rank52.9

Other PubMed-indexed publication

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents.

Alimentary pharmacology & therapeutics · 2026 · PMID 42186906

BACKGROUND: Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are HBsAg-negative and anti-HBc-positive with undetectable HBV DNA are monitored without antiviral prophylaxis, allowing the estimation of HBVr incidence. METHODS: Using administrative claims data from Japan (2008-2022), we included patients receiving immunosuppressive or chemotherapeutic agents who were HBV DNA-negative at baseline, underwent at least two HBV DNA tests, and did not receive antiviral th…

Rank52.5

Other PubMed-indexed publication

Preoperative gut microbiota combined with machine learning for predicting post-hepatectomy liver failure in HBV-related hepatocellular carcinoma: a pilot study.

Frontiers in cellular and infection microbiology · 2026 · PMID 42625750

Rank50.1

Other PubMed-indexed publication

Comparative effectiveness of antiviral therapy according to immune status among pregnant women with chronic hepatitis B virus infection: a retrospective cohort study.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2026 · PMID 41942346

PURPOSE: This study evaluates phase-specific antiviral efficacy of tenofovir disoproxil fumarate (TDF) in pregnant women with hepatitis B virus (HBV) infection, comparing immune-tolerant (IT), inactive carrier (IC), and their corresponding gray zone (GZ-A, GZ-C). Perinatal outcomes and mother-to-child transmission (MTCT) risks were also assessed across these phases. METHODS: In this retrospective study, 717 pregnant women with HBV infection from Nanjing, China (2021-2023) were stratified into IT (n = 317), IC (n = …

Rank49.9

Other PubMed-indexed publication

Survival Outcome Was Better with Liver Resection than with Percutaneous Radiofrequency Ablation in Patients with Very Early-Stage Hepatocellular Carcinoma: A Single-Center Retrospective Study.

Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2026 · PMID 41660702

Gynecologic and obstetric investigation · 2025 · PMID 39820185

OBJECTIVES: The objective of this study was to evaluate the impact of a comprehensive intervention using nursing-sensitive quality indicators on pregnant women with hepatitis B and their newborns. DESIGN: A randomized controlled monocentric trial was conducted from January 2020 to May 2022. Participants/Materials: 80 pregnant women diagnosed with hepatitis B were randomly assigned to either a control group (n = 40) or an experimental group (n = 40). The experimental group received care-sensitive quality indicators …

Rank98.1

Randomized controlled trialResult signal: benefit

Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Cancer research communications · 2026 · PMID 41757470

Rank98.0

Randomized controlled trial

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.

Transplantation and cellular therapy · 2026 · PMID 42150672

Rank97.4

Randomized controlled trial

Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · PMID 40953786

Rank96.6

Randomized controlled trialResult signal: null

Relieving effect of jiao-tune of 5-element music on negative emotions in patients with decompensated hepatitis B virus cirrhosis: A randomized and controlled experiment study.

Medicine · 2024 · PMID 39287243

BACKGROUND: Depression and anxiety are common in patients with decompensated hepatitis B virus (HBV) cirrhosis. This study aimed to evaluate the relieving effects of the jiao-tune of 5-element music on negative emotions in patients with decompensated HBV cirrhosis. METHODS: The patients were randomly allocated into the control group (standard nursing care) and the jiao-tune group (standard nursing care plus a 2-month course of music therapy with the jiao-tune of 5-element music). The negative emotions of patients w…

Rank96.6

Randomized controlled trial

Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.

The American journal of gastroenterology · 2024 · PMID 37561058

INTRODUCTION: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior renal and bone safety. We report updated results through 5 years. METHODS: Patients with HBeAg-negative or HBeAg-positive chronic hepatitis B infection with or without compensated cirrhosis were randomized (2:1) to TAF 25 mg or TDF 300 mg once daily in double-blind (DB) fashion for up to 3 years, followed by o…

Rank96.5

Randomized controlled trial

The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial.

The lancet. Gastroenterology & hepatology · 2026 · PMID 42173110

Rank96.4

Randomized controlled trial

A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.

Journal of hepatology · 2023 · PMID 37062574

BACKGROUND & AIMS: Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved. Discontinuation of NUC treatment may lead to functional cure; however, to date, the evidence for this has been based on small or non-randomized clinical trials. The STOP-NUC trial was designed with the aim of increasing the HBsAg loss rate using a NUC treatment interruption approach. METHODS: In this multicenter, randomized-co…

Rank96.3

Randomized controlled trial

GSK3389404, an N-acetyl galactosamine-conjugated antisense oligonucleotide (ASO), was in clinical development for chronic hepatitis B (CHB) treatment. Few studies have examined ASOs in Asian participants. In this analysis, the plasma pharmacokinetics (PK) of GSK3389404 were characterized and compared in patients with CHB across the Asia-Pacific region (N = 64), including mainland China (n = 16), Hong Kong (n = 8), Japan (n = 21), South Korea (n = 12), Singapore (n = 4), and the Philippines (n = 3), from a phase 2a,…

Rank95.6

Randomized controlled trialResult signal: null

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial.

Journal of viral hepatitis · 2026 · PMID 41608776

Rank95.4

Randomized controlled trialResult signal: mixed

Enhancing Hepatitis B and C Prevention Among People Who Use Drugs: Evaluating an Educational Intervention at a Drop-In Center in Southwest Iran based on Protection Motivation Theory.

BMC public health · 2025 · PMID 41126184

Research information notice

Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.